Effects NNS O
of IN O
a DT O
leukemia-associated NN O
gain-of-function NN O
mutation NN O
of IN O
SHP-2 NNP O
phosphatase NN O
on IN O
interleukin-3 JJ O
signaling NN O
. . O

Mutations NNPS B-Var
in IN O
SHP-2 NNP B-Gene
phosphatase NN B-Enzyme
that WDT O
cause VBP O
hyperactivation NN B-PosReg
of IN O
its PRP$ O
catalytic JJ B-MPA
activity NN I-MPA
have VBP O
been VBN O
identified VBN O
in IN O
human JJ B-Disease
leukemias NNS I-Disease
, , O
particularly RB O
juvenile JJ B-Disease
myelomonocytic JJ I-Disease
leukemia NN I-Disease
, , O
which WDT O
is VBZ O
characterized VBN O
by IN O
hypersensitivity NN O
of IN O
myeloid NN O
progenitor NN O
cells NNS O
to IN O
granulocyte NN O
macrophage NN O
colony-stimulating NN O
factor NN O
and CC O
interleukin JJ O
( -LRB- O
IL)-3 JJ O
. . O

However RB O
, , O
the DT O
molecular JJ O
mechanisms NNS O
by IN O
which WDT O
gain-of-function VB O
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS O
of IN O
SHP-2 NNP O
induce VB O
hematopoietic JJ O
malignancies NNS O
are VBP O
not RB O
fully RB O
understood VBN O
. . O

Our PRP$ O
previous JJ O
studies NNS O
have VBP O
shown VBN O
that IN O
SHP-2 NNP O
plays VBZ O
an DT O
essential JJ O
role NN O
in IN O
IL-3 CD O
signal NN O
transduction NN O
in IN O
both CC O
catalytic-dependent JJ O
and CC O
-independent : O
manners NNS O
and CC O
that DT O
overexpression NN O
( -LRB- O
5-6-fold CD O
) -RRB- O
of IN O
wild JJ O
type NN O
( -LRB- O
WT NNP O
) -RRB- O
SHP-2 NNP O
attenuates NNS O
IL-3-mediated VBD O
hematopoietic JJ O
cell NN O
function NN O
through IN O
accelerated JJ O
dephosphorylation NN O
of IN O
STAT5 NNP O
. . O

These DT O
results NNS O
raised VBD O
the DT O
possibility NN O
that IN O
SHP-2-associated VBN O
leukemias NNS O
are VBP O
not RB O
solely RB O
attributed VBN O
to IN O
the DT O
increased VBN O
catalytic JJ O
activity NN O
of IN O
GOF NNP O
mutant JJ O
SHP-2 NNP O
. . O

GOF NN O
mutant JJ O
SHP-2 NNP O
must MD O
have VB O
gained VBN O
additional JJ O
capacities NNS O
. . O

To TO O
test VB O
this DT O
possibility NN O
, , O
we PRP O
investigated VBD O
effects NNS O
of IN O
a DT O
GOF NN O
mutation NN O
of IN O
SHP-2 NNP O
( -LRB- O
SHP-2 NNP O
E76 NNP O
K NNP O
) -RRB- O
on IN O
hematopoietic JJ O
cell NN O
function NN O
and CC O
IL-3 CD O
signal NN O
transduction NN O
by IN O
comparing VBG O
with IN O
those DT O
of IN O
overexpressed VBN O
WT NNP O
SHP-2 NNP O
. . O

Our PRP$ O
results NNS O
showed VBD O
that IN O
SHP-2 NNP B-Gene
E76 NNP B-Var
K NNP I-Var
mutation NN O
caused VBD O
myeloproliferative JJ B-Disease
disease NN I-Disease
in IN I-Disease
mice NNS I-Disease
, , O
while IN O
overexpression NN O
of IN O
WT NNP O
SHP-2 NNP O
decreased VBD O
hematopoietic JJ O
potential NN O
of IN O
the DT O
transduced JJ O
cells NNS O
in IN O
recipient NN O
animals NNS O
. . O

The DT O
E76 NNP B-Var
K NNP I-Var
mutation NN I-Var
in IN I-Var
the DT I-Var
N-terminal NN I-Var
Src NNP I-Var
homology NN I-Var
2 CD I-Var
domain NN O
increased VBN B-PosReg
interactions NNS B-Interaction
of IN O
mutant JJ B-Var
SHP-2 NNP B-Gene
with IN O
Grb2 NNP B-Protein
, , O
Gab2 NNP O
, , O
and CC O
p85 NN O
, , O
leading VBG O
to IN O
hyperactivation NN B-PosReg
of IN O
IL-3-induced NNP B-Pathway
Erk NNP I-Pathway
and CC I-Pathway
phosphatidylinositol VB I-Pathway
3-kinase NN I-Pathway
( -LRB- I-Pathway
PI3 NNP I-Pathway
K NNP O
) -RRB- O
pathways NNS O
. . O

In IN O
addition NN O
, , O
despite IN O
the DT O
substantial JJ O
increase NN B-PosReg
in IN O
the DT O
catalytic JJ B-MPA
activity NN I-MPA
, , O
dephosphorylation NN B-MPA
of IN I-MPA
STAT5 NNP I-MPA
by IN O
SHP-2 NNP B-Gene
E76 NNP B-Var
K NNP O
was VBD O
dampened VBN B-NegReg
. . O

Furthermore RB O
, , O
catalytically RB B-Var
inactive NN I-Var
SHP-2 NNP I-Var
E76 NNP I-Var
K NNP I-Var
with IN I-Var
an DT I-Var
additional JJ I-Var
C459S NN I-Var
mutation NN O
retained VBD O
the DT O
capability NN O
to TO O
increase VB B-PosReg
the DT O
interaction NN B-Interaction
with IN O
Gab2 NN B-Protein
and CC O
to TO O
enhance VB B-PosReg
the DT O
activation NN B-Pathway
of IN I-Pathway
the DT I-Pathway
PI3 NNP I-Pathway
K NNP I-Pathway
Genetic JJ O
modifiers NNS O
of IN O
the DT O
Drosophila NNP O
blue JJ O
cheese NN O
gene NN O
link NN O
defects NNS O
in IN O
lysosomal JJ O
transport NN O
with IN O
decreased VBN O
life NN O
span NN O
and CC O
altered VBD O
ubiquitinated-protein JJ O
profiles NNS O
. . O

Defects NNS O
in IN O
lysosomal JJ O
trafficking NN O
pathways NNS O
lead VBP O
to IN O
decreased VBN O
cell NN O
viability NN O
and CC O
are VBP O
associated VBN O
with IN O
progressive JJ O
disorders NNS O
in IN O
humans NNS O
. . O

Previously RB O
we PRP O
have VBP O
found VBN O
that IN O
loss-of-function NN O
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS B-Var
in IN O
the DT O
Drosophila NNP B-Gene
gene NN I-Gene
blue JJ I-Gene
cheese NN I-Gene
( -LRB- O
bchs NNS O
) -RRB- O
lead VB O
to IN O
reduced VBN B-NegReg
adult NN B-CPA
life NN I-CPA
span NN I-CPA
, , O
increased VBN B-PosReg
neuronal JJ B-CPA
death NN I-CPA
, , O
and CC O
widespread JJ B-CPA
CNS NN I-CPA
degeneration NN B-NegReg
that WDT O
is VBZ O
associated VBN O
with IN O
the DT O
formation NN O
of IN O
ubiquitinated-protein JJ O
aggregates NNS O
. . O

To TO O
identify VB O
potential JJ O
genes NNS O
that WDT O
participate VBP O
in IN O
the DT O
bchs JJ O
functional JJ O
pathway NN O
, , O
we PRP O
conducted VBD O
a DT O
genetic JJ O
modifier NN O
screen NN O
based VBN O
on IN O
alterations NNS O
of IN O
an DT O
eye NN O
phenotype NN O
that WDT O
arises VBZ O
from IN O
high-level JJ O
overexpression NN O
of IN O
Bchs NNP O
. . O

We PRP O
found VBD O
that IN O
mutations NNS O
in IN O
select JJ O
autophagic JJ O
and CC O
endocytic JJ O
trafficking NN O
genes NNS O
, , O
defects NNS O
in IN O
cytoskeletal JJ O
and CC O
motor NN O
proteins NNS O
, , O
as RB O
well RB O
as IN O
mutations NNS O
in IN O
the DT O
SUMO NNS O
and CC O
ubiquitin JJ O
signaling NN O
pathways NNS O
behave VBP O
as IN O
modifiers NNS O
of IN O
the DT O
Bchs NNP O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
eye NN O
phenotype NN O
. . O

Individual JJ O
mutant JJ O
alleles NNS O
that WDT O
produced VBD O
viable JJ O
adults NNS O
were VBD O
further RB O
examined VBN O
for IN O
bchs-like NNS O
phenotypes NNS O
. . O

Mutations NNS B-Var
in IN O
several JJ O
lysosomal JJ B-Gene
trafficking NN I-Gene
genes NNS I-Gene
resulted VBD O
in IN O
significantly RB O
decreased VBN B-NegReg
adult NN B-CPA
life NN I-CPA
spans NNS I-CPA
and CC O
several JJ O
mutants NNS O
showed VBD O
changes NNS B-Reg
in IN O
ubiquitinated JJ B-MPA
protein NN I-MPA
profiles NNS I-MPA
Isolation NN O
and CC O
characterization NN O
of IN O
a DT O
novel JJ O
human JJ O
RGS NN O
mutant JJ O
displaying VBG O
gain-of-function NN O
activity NN O
. . O

Regulator NNP O
of IN O
G NNP O
protein NN O
signaling NN O
( -LRB- O
RGS NN O
) -RRB- O
proteins NNS O
play VBP O
a DT O
crucial JJ O
role NN O
in IN O
the DT O
adaptation NN O
of IN O
cells NNS O
to IN O
stimulation NN B-PosReg
by IN O
G NNP B-Protein
protein-coupled NN I-Protein
receptors NNS I-Protein
via IN O
heterotrimeric JJ B-Protein
G NNP I-Protein
proteins NNS I-Protein
. . O

Alterations NNS B-Var
in IN O
RGS NN B-Protein
function NN O
have VBP O
been VBN O
implicated VBN B-Reg
in IN O
a DT O
wide JJ O
range NN O
of IN O
disease NN B-Disease
states NNS O
, , O
leading VBG O
to IN O
many JJ O
researchers NNS O
focusing VBG O
on IN O
controlling VBG O
the DT O
action NN O
of IN O
these DT O
regulatory JJ O
proteins NNS O
. . O

Previous JJ O
studies NNS O
have VBP O
centered VBN O
on IN O
reducing VBG B-NegReg
or CC O
inhibiting VBG B-NegReg
the DT O
action NN O
of IN O
RGS NNP B-Protein
proteins NNS I-Protein
, , O
utilizing VBG O
inactive NN O
mutants NNS O
or CC O
small JJ O
molecular JJ O
RGS NN O
inhibitors NNS O
. . O

Here RB O
we PRP O
describe VBP O
the DT O
isolation NN O
and CC O
characterization NN O
of IN O
a DT O
novel JJ O
human NN O
RGS4 NNP B-Var
mutant JJ I-Var
which WDT O
displays NNS O
enhanced VBN B-PosReg
or CC O
gain-of-function JJ B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
activity NN O
. . O

RGS4(S30C NN O
) -RRB- O
demonstrates VBZ O
GOF NN O
activity NN O
both CC O
in IN O
an DT O
in IN O
vivo NN O
yeast-based NN B-Pathway
signalling NN I-Pathway
pathway NN I-Pathway
and CC O
in IN O
vitro FW O
against IN O
the DT O
Galpha(o1 NNP B-Protein
) -RRB- I-Protein
subunit NN I-Protein
contained VBN I-Protein
in IN I-Protein
an DT I-Protein
alpha(2A)-adrenoreceptor-Galpha(o1)(C351I NN I-Protein
) -RRB- I-Protein
fusion NN O
protein NN O
. . O

Mutational JJ O
analysis NN O
of IN O
serine NN O
30 CD O
identified VBD O
a DT O
number NN O
of IN O
alternative JJ O
substitutions NNS O
that WDT O
result VBP O
in IN O
GOF NN O
activity NN O
. . O

GOF NN O
activity NN O
was VBD O
retained VBN O
upon IN O
transposition NN O
of IN O
the DT O
serine JJ O
30-cysteine CD O
mutation NN O
to IN O
the DT O
equivalent JJ O
serine NN O
residue NN O
in IN O
human NN O
RGS16 NNP O
. . O

As IN O
with IN O
previously RB O
identified VBN O
GOF NN O
mutants NNS O
, , O
RGS4(S30C NN B-Var
/ SYM O
S30F NNP O
/ SYM O
S30 NNP O
K NNP O
) -RRB- O
demonstrate VB O
increased VBD O
steady JJ O
state NN O
protein NN O
levels NNS O
, , O
however RB O
these DT O
mutants NNS O
also RB O
demonstrate VBP O
enhanced VBN O
GAP NNP O
activity NN O
through IN O
an DT O
additional JJ O
mechanism NN O
distinct JJ O
from IN O
the DT O
increased VBN O
protein NN O
content NN O
. . O

The DT O
identification NN O
of IN O
human JJ O
RGS NN O
mutants NNS O
with IN O
GOF NN O
activity NN O
may MD O
provide VB O
novel JJ O
therapeutic JJ O
agents NNS O
for IN O
the DT O
treatment NN O
of IN O
signaling-based NN O
diseases NNS O
and CC O
the DT O
ability NN O
to TO O
transpose VB O
these DT O
mutations NNS O
to IN O
other JJ O
human JJ O
RGS NN O
proteins NNS O
extends VBZ O
their PRP$ O
application NN O
to IN O
multiple JJ O
pathways NNS O
. . O

Conditional JJ O
RNA NNP O
interference NN O
in IN O
vivo NN O
to TO O
study VB O
mutant JJ O
p53 NN O
oncogenic JJ O
gain NN O
of IN O
function NN O
on IN O
tumor NN O
malignancy NN O
. . O

Mutant NNP B-Var
p53 NN B-Gene
proteins NNS B-Protein
are VBP O
thought VBN O
to TO O
have VB O
acquired VBN O
a DT O
" `` O
gain NN O
of IN O
function NN O
" '' O
( -LRB- O
GOF NN O
) -RRB- O
activity NN O
that WDT O
mainly RB O
contributes VBZ B-PosReg
to IN O
tumor NN B-CPA
aggressiveness NN I-CPA
. . O

Previously RB O
we PRP O
reported VBD O
that IN O
constitutive JJ O
downregulation NN B-NegReg
of IN O
mutant JJ B-Var
p53 NN B-Gene
by IN O
RNA NNP B-MPA
interference NN I-MPA
reduces VBZ B-NegReg
the DT O
tumorigenicity NN B-CPA
of IN I-CPA
cancer NN I-CPA
cells NNS I-CPA
in IN I-CPA
an DT I-CPA
animal NN I-CPA
model NN I-CPA
; : O
however RB O
, , O
effects NNS O
of IN O
adaptation NN O
to IN O
long-term JJ O
mutant JJ O
p53 NN O
inhibition NN O
could MD O
not RB O
be VB O
excluded VBN O
. . O

To TO O
address VB O
this DT O
point NN O
, , O
mimicking VBG O
more JJR O
physiological JJ O
conditions NNS O
, , O
we PRP O
now RB O
describe VBP O
the DT O
establishment NN O
of IN O
a DT O
lentiviral-based NN O
system NN O
for IN O
conditional JJ O
interference NN O
with IN O
mutant JJ O
p53 NN O
expression NN O
. . O

In IN O
vivo NN O
studies NNS O
assessed VBD O
the DT O
efficacy NN O
of IN O
conditional JJ B-MPA
RNA NNP I-MPA
interference NN I-MPA
in IN O
inhibiting VBG B-NegReg
gain NN O
of IN O
function NN O
activity NN B-MPA
of IN O
mutant JJ B-Var
p53 NN B-Gene
proteins NNS B-Protein
by IN O
reducing VBG O
tumor NN O
growth NN O
ability NN O
. . O

Moreover RB O
by IN O
using VBG O
this DT O
system NN O
, , O
microarray JJ O
data NNS O
were VBD O
validated VBN O
in IN O
vitro FW O
and CC O
in IN O
vivo NN O
and CC O
putative JJ O
mutant JJ O
p53 NN O
target NN O
genes NNS O
that WDT O
may MD O
contribute VB O
to IN O
its PRP$ O
gain NN O
of IN O
function NN O
effects NNS O
in IN O
cancer NN O
were VBD O
identified VBN O
. . O

Results NNS O
are VBP O
confirmatory JJ O
that IN O
depletion NN B-MPA
of IN O
mutant JJ B-Var
p53 NN B-Gene
protein NN B-Protein
impacts NNS B-Reg
on IN O
tumor NN B-CPA
malignancy NN I-CPA
Identification NN O
and CC O
functional JJ O
analysis NN O
of IN O
novel JJ O
variants NNS O
of IN O
the DT O
human JJ O
melanocortin NN O
1 CD O
receptor NN O
found VBN O
in IN O
melanoma NN O
patients NNS O
. . O

The DT O
melanocortin NN O
1 CD O
receptor NN O
, , O
a DT O
Gs NNP O
protein-coupled NN O
receptor NN O
expressed VBN O
in IN O
epidermal JJ O
melanocytes NNS O
, , O
is VBZ O
a DT O
major JJ O
determinant NN O
of IN O
skin NN O
pigmentation NN O
and CC O
phototype NN O
and CC O
an DT O
important JJ O
contributor NN O
to IN O
melanoma NN O
risk NN O
. . O

MC1R NN O
activation NN O
stimulates VBZ O
synthesis NN O
of IN O
black JJ O
, , O
strongly RB O
photoprotective JJ O
eumelanin JJ O
pigments NNS O
. . O

Several JJ O
MC1R NNP O
alleles NNS O
are VBP O
associated VBN O
with IN O
red JJ O
hair NN O
, , O
fair JJ O
skin NN O
, , O
increased VBD O
sensitivity NN O
to IN O
ultraviolet JJ O
radiation NN O
, , O
and CC O
increased VBD O
skin NN O
cancer NN O
risk NN O
. . O

The DT O
MC1R NNP O
gene NN O
is VBZ O
highly RB O
polymorphic JJ O
, , O
but CC O
only RB O
a DT O
few JJ O
naturally RB O
occurring VBG O
alleles NNS O
have VBP O
been VBN O
functionally RB O
characterized VBN O
, , O
which WDT O
complicates VBZ O
the DT O
establishment NN O
of IN O
accurate JJ O
correlations NNS O
between IN O
the DT O
signaling NN O
properties NNS O
of IN O
mutant JJ O
alleles NNS O
and CC O
defined VBD O
cutaneous JJ O
phenotypes NNS O
. . O

We PRP O
report VBP O
the DT O
functional JJ O
characterization NN O
of IN O
six CD O
MC1R NNP O
alleles NNS O
found VBN O
in IN O
Spanish JJ O
melanoma NN B-Disease
patients NNS O
. . O

Two CD O
variants NNS O
( -LRB- O
c.152T NN O
> XX O
C NNP O
, , O
p NN O
. . O

Val51Ala JJ O
and CC O
c.865T VB O
> XX O
C NNP O
, , O
p NN O
. . O

Cys289Arg NNP O
) -RRB- O
have VBP O
never RB O
been VBN O
described VBN O
, , O
and CC O
the DT O
others NNS O
( -LRB- O
c.112G JJ O
> XX O
A NNP O
, , O
p NN O
. . O

Val38Met RB O
; : O
c.122C NNP O
> XX O
T NNP O
, , O
p NN O
. . O

Ser41Phe NNS O
; : O
c.383T NNP O
> XX O
C NNP O
, , O
p NN O
. . O

Met128Thr NN O
; : O
and CC O
c.842A NN O
> XX O
G NN O
, , O
p NN O
. . O

Asn281Ser RB O
) -RRB- O
have VBP O
not RB O
been VBN O
analyzed VBN O
for IN O
function NN O
. . O

p LS B-Var
. . O

Asn281Ser DT O
corresponds VBZ O
to IN O
a DT O
functionally RB O
silent JJ B-NegReg
polymorphism NN B-MPA
. . O

The DT O
other JJ O
mutations NNS O
are VBP O
associated VBN O
with IN O
varying VBG O
degrees NNS O
of IN O
loss NN O
of IN O
function NN O
( -LRB- O
LOF NNP O
) -RRB- O
, , O
from IN O
moderate JJ O
decreases NNS B-NegReg
in IN O
coupling VBG B-MPA
to IN O
the DT O
cAMP NN B-Pathway
pathway NN I-Pathway
( -LRB- O
p NN B-Var
. . O

Val38Met RB O
and CC O
p LS B-Var
. . O

Val51Ala RB O
) -RRB- O
to IN O
nearly RB O
complete JJ O
absence NN B-NegReg
of IN O
functional JJ B-MPA
coupling NN I-MPA
( -LRB- O
p NN B-Var
. . O

Ser41Phe VB O
, , O
p NN B-Var
. . O

Met128Thr NN O
, , O
and CC O
p LS B-Var
. . O

Cys289Arg NNP O
) -RRB- O
. . O

The DT O
LOF NNP O
p NN B-Var
. . O

Met128Thr NN O
and CC O
p NN B-Var
. . O

Cys289Arg NNP O
mutants NNS O
are VBP O
trafficked VBN O
to IN O
the DT O
cell NN O
surface NN O
, , O
but CC O
are VBP O
unable JJ B-NegReg
to TO O
bind VB B-Interaction
agonists NNS O
efficiently RB O
. . O

Conversely RB O
, , O
LOF NNP O
of IN O
p XX B-Var
. . I-Var
Val38Met RB I-Var
, , I-Var
p XX O
. . O

Ser41Phe VB O
, , O
and CC O
p LS O
. . O

Val51Ala JJ O
is VBZ O
due JJ O
to IN O
reduced JJ B-NegReg
cell NN B-CPA
surface NN I-CPA
expression NN I-CPA
Elevated JJ O
expression NN O
of IN O
p53 NN O
gain-of-function JJ O
mutation NN O
R175H NNS O
in IN O
endometrial JJ O
cancer NN O
cells NNS O
can MD O
increase VB O
the DT O
invasive JJ O
phenotypes NNS O
by IN O
activation NN O
of IN O
the DT O
EGFR NNP O
/ SYM O
PI3K NNP O
/ SYM O
AKT NNP O
pathway NN O
. . O

BACKGROUND NNP O
: : O
p53 NN O
is VBZ O
the DT O
most RBS O
commonly RB O
mutated VBN O
tumor NN O
suppressor NN O
gene NN O
in IN O
human JJ O
cancers NNS O
. . O

In IN O
addition NN O
to IN O
the DT O
loss NN O
of IN O
tumor NN O
suppression NN O
function NN O
and CC O
exertion NN O
of IN O
dominant-negative JJ O
effects NNS O
over IN O
the DT O
remaining VBG O
wild-type JJ O
protein NN O
, , O
several JJ O
p53 NN O
mutants NNS O
can MD O
gain VB O
novel JJ O
oncogenic JJ O
functions NNS O
( -LRB- O
gain-of-function NN O
, , O
GOF NNP O
) -RRB- O
that WDT O
actively RB O
regulate VBP O
cancer NN O
development NN O
and CC O
progression NN O
. . O

In IN O
human JJ O
endometrial NN O
cancer NN O
, , O
p53 NN B-Gene
mutation NN B-Var
is VBZ O
more RBR O
often RB O
associated VBN B-Reg
with IN O
aggressive JJ B-Disease
nonendometrioid JJ I-Disease
cancer NN I-Disease
. . O

However RB O
, , O
it PRP O
was VBD O
unknown JJ O
if IN O
p53 NN O
mutants NNS O
contributed VBD O
to IN O
endometrial JJ O
cancer NN O
progression NN O
through IN O
the DT O
GOF NN O
properties NNS O
. . O

METHODS NNS O
: : O
To TO O
clarify VB O
the DT O
relationship NN O
between IN O
expression NN O
of IN O
p53 NN O
GOF NN O
mutation NN O
( -LRB- O
p53-R175H NNP O
) -RRB- O
and CC O
invasive JJ O
potential NN O
of IN O
human JJ O
endometrial NN O
cancer NN O
KLE NNP O
cells NNS O
, , O
we PRP O
tested VBD B-Reg
the DT O
consequences NNS O
of IN O
up-regulation NN B-PosReg
and CC O
down-regulation NN B-NegReg
of IN O
p53-R175H NNP O
in IN O
KLE NNP O
cells NNS O
by IN O
inducing VBG B-Reg
p53-R175H NNS B-Protein
expression NN I-Protein
vector NN I-Protein
or CC O
suppressing VBG B-NegReg
the DT O
p53 NN B-Gene
gene NN I-Gene
with IN O
short JJ O
hairpin NN O
RNA NNP O
. . O

RESULTS NNS O
: : O
We PRP O
found VBD O
that IN O
forced VBN O
over-expression IN B-PosReg
of IN O
p53-R175H NNP B-Protein
significantly RB O
promoted VBD O
cell NN O
migration NN O
and CC O
invasion NN O
, , O
and CC O
induced VBN O
activation NN O
of IN O
the DT O
epidermal JJ O
growth NN O
factor NN O
receptor NN O
( -LRB- O
EGFR)/phosphatidylinositol NNP O
3-kinase NNP O
( -LRB- O
PI3K)/AKT JJ O
pathway NN O
. . O

Conversely RB O
, , O
suppression NN O
of IN O
p53-R175H NNP O
with IN O
short JJ O
hairpin NN O
RNA NNP O
significantly RB O
inhibited VBD O
cell NN O
migration NN O
and CC O
invasion NN O
, , O
and CC O
resulted VBD O
in IN O
attenuation NN O
of IN O
EGFR NNP O
/ SYM O
PI3K NNP O
/ SYM O
AKT NNP O
pathway NN O
. . O

CONCLUSION NN O
: : O
These DT O
findings NNS O
show VBP O
for IN O
the DT O
first JJ O
time NN O
that WDT O
elevated JJ O
expression NN O
of IN O
p53-R175H NNP O
mutant JJ O
may MD O
exert VB O
gain-of-function NN O
activity NN O
to TO O
activate VB O
the DT O
EGFR NNP O
/ SYM O
PI3K NNP O
/ SYM O
AKT NNP O
pathway NN O
and CC O
thus RB O
may MD O
contribute VB O
to IN O
the DT O
invasive JJ O
phenotype NN O
in IN O
endometrial JJ O
cancer NN O
. . O

The DT O
tyrosine JJ O
phosphatase NN O
Shp2 VBP O
in IN O
development NN O
and CC O
cancer NN O
. . O

Deregulation NNP O
of IN O
signaling NN O
pathways NNS O
, , O
through IN O
mutation NN O
or CC O
other JJ O
molecular JJ O
changes NNS O
, , O
can MD O
ultimately RB O
result VB O
in IN O
disease NN O
. . O

The DT O
tyrosine JJ O
phosphatase NN O
Shp2 NN O
has VBZ O
emerged VBN O
as IN O
a DT O
major JJ O
regulator NN O
of IN O
receptor NN O
tyrosine JJ O
kinase NN O
( -LRB- O
RTK NNP O
) -RRB- O
and CC O
cytokine NN O
receptor NN O
signaling NN O
. . O

In IN O
the DT O
last JJ O
decade NN O
, , O
germline NN O
mutations NNS O
in IN O
the DT O
human JJ O
PTPN11 NN O
gene NN O
, , O
encoding VBG O
Shp2 NN O
, , O
were VBD O
linked VBN O
to IN O
Noonan NNP O
( -LRB- O
NS NNP O
) -RRB- O
and CC O
LEOPARD NNP O
syndromes NNS O
, , O
two CD O
multisymptomatic JJ O
developmental JJ O
disorders NNS O
that WDT O
are VBP O
characterized VBN O
by IN O
short JJ O
stature NN O
, , O
craniofacial NN O
defects NNS O
, , O
cardiac JJ O
defects NNS O
, , O
and CC O
mental JJ O
retardation NN O
. . O

Somatic JJ O
Shp2 NN B-Gene
mutations NNS B-Var
are VBP O
also RB O
associated VBN B-Reg
with IN O
several JJ O
types NNS O
of IN O
human JJ O
malignancies NNS O
, , O
such JJ O
as IN O
the DT O
most RBS O
common JJ O
juvenile JJ B-Disease
leukemia NN I-Disease
, , O
juvenile JJ B-Disease
myelomonocytic JJ I-Disease
leukemia NN I-Disease
( -LRB- O
JMML NNP O
) -RRB- O
. . O

Whereas IN O
NS NNP B-Disease
and CC O
JMML NNP B-Disease
are VBP O
caused VBN O
by IN O
gain-of-function NN B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
of IN O
Shp2 JJ B-Gene
, , O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS B-Var
are VBP O
thought VBN O
to TO O
be VB O
associated VBN O
with IN O
LEOPARD NNP B-Disease
syndrome NN I-Disease
Mutant JJ B-Var
p53 VBP B-Gene
facilitates NNS B-PosReg
somatic JJ B-CPA
cell NN I-CPA
reprogramming NN I-CPA
and CC O
augments VBZ B-NegReg
the DT O
malignant JJ B-CPA
potential NN I-CPA
of IN I-CPA
reprogrammed JJ I-CPA
cells NNS I-CPA
. . O

p53 NN B-Gene
deficiency NN B-Var
enhances VBZ B-PosReg
the DT O
efficiency NN O
of IN O
somatic JJ B-CPA
cell NN I-CPA
reprogramming VBG I-CPA
to IN O
a DT O
pluripotent NN O
state NN O
. . O

As IN O
p53 NN O
is VBZ O
usually RB O
mutated VBN O
in IN O
human JJ O
tumors NNS O
and CC O
many JJ O
mutated VBN B-Var
forms NNS I-Var
of IN O
p53 NN B-Gene
gain JJ B-PosReg
novel JJ O
activities NNS B-MPA
, , O
we PRP O
studied VBD O
the DT O
influence NN O
of IN O
mutant JJ O
p53 NN O
( -LRB- O
mut-p53 NN O
) -RRB- O
on IN O
somatic JJ O
cell NN O
reprogramming NN O
. . O

Our PRP$ O
data NNS O
indicate VBP O
a DT O
novel JJ O
gain NN B-PosReg
of IN O
function NN B-MPA
( -LRB- O
GOF NN O
) -RRB- O
property NN O
for IN O
mut-p53 NN B-Var
, , O
which WDT O
markedly RB O
enhanced VBD B-PosReg
the DT O
efficiency NN O
of IN O
the DT O
reprogramming VBG B-CPA
process NN I-CPA
compared VBN O
with IN O
p53 NN O
deficiency NN O
. . O

Importantly RB O
, , O
this DT O
novel JJ O
activity NN B-MPA
of IN O
mut-p53 NN B-Var
induced JJ O
alterations NNS B-Reg
in IN O
the DT O
characteristics NNS B-CPA
of IN I-CPA
the DT I-CPA
reprogrammed JJ I-CPA
cells NNS I-CPA
. . O

Although IN O
p53 NN O
knockout NN O
( -LRB- O
KO NNP O
) -RRB- O
cells NNS O
reprogrammed VBN O
with IN O
only JJ O
Oct4 NNP O
and CC O
Sox2 NNP O
maintained VBD O
their PRP$ O
pluripotent NN B-MPA
capacity NN I-MPA
in IN O
vivo NN O
, , O
reprogrammed VBD O
cells NNS O
expressing VBG O
mutant JJ B-Var
p53 NN B-Gene
lost VBN B-NegReg
this DT O
capability NN O
and CC O
gave VBD B-Reg
rise NN I-Reg
to IN O
malignant JJ B-CPA
tumors NNS I-CPA
. . O

This DT O
novel JJ O
GOF NN O
of IN O
mut-p53 NN O
is VBZ O
not RB O
attributed VBN O
to IN O
its PRP$ O
effect NN O
on IN O
proliferation NN O
, , O
as IN O
both DT O
p53 NN O
KO NNP O
and CC O
mut-p53 NN O
cells NNS O
displayed VBD O
similar JJ O
proliferation NN O
rates NNS O
. . O

In IN O
addition NN O
, , O
we PRP O
demonstrate VBP O
an DT O
oncogenic JJ B-MPA
activity NN I-MPA
of IN O
Klf4 NNP O
, , O
as IN O
its PRP$ O
overexpression NN B-PosReg
in IN O
either DT O
p53 NN B-Var
KO NNP I-Var
or CC I-Var
mut-p53 NN I-Var
cells NNS O
induced VBD B-PosReg
aggressive JJ B-CPA
tumors NNS I-CPA
. . O

Overall RB O
, , O
our PRP$ O
data NNS O
show VBP O
that WDT O
reprogrammed VBD O
cells NNS O
with IN O
the DT O
capacity NN O
to TO O
differentiate VB O
into IN O
the DT O
three CD O
germ JJ O
layers NNS O
in IN O
vitro FW O
can MD O
form VB O
malignant JJ O
tumors NNS O
, , O
suggesting VBG O
that IN O
in IN O
genetically RB O
unstable JJ O
cells NNS O
, , O
such JJ O
as IN O
those DT O
in IN O
which WDT O
p53 NN B-Gene
is VBZ O
mutated VBN B-Var
, , O
reprogramming VBG B-CPA
may MD O
result VB B-Reg
in IN I-Reg
the DT O
generation NN O
of IN O
cells NNS B-CPA
with IN I-CPA
malignant JJ I-CPA
tumor-forming NN I-CPA
potential NN I-CPA
The DT O
combined JJ O
impact NN O
of IN O
CYP2C19 NNP O
and CC O
CYP2B6 NNS O
pharmacogenetics NNS O
on IN O
cyclophosphamide NN O
bioactivation NN O
. . O

AIMS NNP O
: : O
The DT O
role NN O
of IN O
CYP NNP O
pharmacogenetics NNS O
in IN O
the DT O
bioactivation NN O
of IN O
cyclophosphamide NN O
is VBZ O
still RB O
controversial JJ O
. . O

Recent JJ O
clinical JJ O
studies NNS O
have VBP O
suggested VBN O
a DT O
role NN O
for IN O
either DT O
CYP2C19 NNP O
or CC O
CYP2B6 NNS O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
was VBD O
to TO O
clarify VB O
the DT O
role NN O
of IN O
these DT O
pharmacogenes NNS O
. . O

METHODS NNS O
: : O
We PRP O
used VBD O
a DT O
combined VBN O
in IN O
vitro-in FW O
vivo NN O
approach NN O
to TO O
determine VB O
the DT O
role NN O
of IN O
these DT O
pharmacogenes NNS O
in IN O
the DT O
bioactivation NN O
of IN O
the DT O
prodrug NN O
to IN O
4-hydroxy JJ O
cyclophosphamide NN O
( -LRB- O
4-OHCP CD O
) -RRB- O
. . O

Cyclophosphamide NN O
metabolism NN O
was VBD O
determined VBN O
in IN O
a DT O
human JJ O
liver NN O
biobank NN O
( -LRB- O
n= DT O
14 CD O
) -RRB- O
and CC O
in IN O
patients NNS O
receiving VBG O
the DT O
drug NN O
for IN O
treatment NN O
of IN O
lupus NN O
nephritis NN O
( -LRB- O
n= NN O
16 CD O
) -RRB- O
RESULTS NNS O
: : O
In IN O
livers NNS O
of IN O
known VBN O
CYP2C19 NNP O
and CC O
CYP2B6 NNS O
genotype NN O
and CC O
protein NN O
expression NN O
we PRP O
observed VBD O
that IN O
there EX O
was VBD O
a DT O
combined JJ B-Interaction
role NN O
for IN O
both DT O
CYP2C19 NNP B-Var
and CC O
CYP2B6 NNS B-Var
in IN O
the DT O
bioactivation NN B-MPA
of IN I-MPA
cyclophosphamide NN I-MPA
in IN I-MPA
vitro FW I-MPA
. . O

The DT O
presence NN O
of IN O
at RB O
least RBS O
one CD O
loss NN O
of IN O
function NN O
( -LRB- O
LoF NN O
) -RRB- O
allele NN O
at IN O
either DT O
CYP2C19 NNP B-Var
or CC O
CYP2B6 NNS B-Var
resulted VBD O
in IN O
a DT O
significant JJ O
decrease NN B-NegReg
in IN O
both DT O
V(max NN B-MPA
) -RRB- I-MPA
( -LRB- I-MPA
P= NN I-MPA
0.028 CD I-MPA
) -RRB- I-MPA
and CC I-MPA
CL(int NN O
) -RRB- O
( -LRB- O
P= JJ O
0.0017 CD O
) -RRB- O
compared VBN O
with IN O
livers NNS O
with IN O
no DT O
LoF NNP O
alleles NNS O
. . O

This DT O
dual JJ O
genotype NN O
relationship NN O
was VBD O
also RB O
observed VBN O
in IN O
a DT O
preliminary JJ O
clinical JJ O
study NN O
, , O
with IN O
patients NNS O
who WP O
had VBD O
LoF IN O
allele NN O
at IN O
either DT O
CYP2C19 NNP B-Var
or CC O
CYP2B6 NNS B-Var
also RB O
displaying VBG O
significantly RB O
( -LRB- O
P= NNP O
0.0316 CD O
) -RRB- O
lower JJR B-NegReg
bioactivation NN B-MPA
of IN I-MPA
cyclophosphamide NN I-MPA
. . O

The DT O
mean JJ O
4-OHCP CD O
: : O
CP NNP O
bioactivation NN O
ratio NN O
was VBD O
0.0014 CD O
( -LRB- O
95 CD O
% NN O
CI NN O
0.0007 CD O
, , O
0.002 CD O
) -RRB- O
compared VBN O
with IN O
0.0071 CD O
( -LRB- O
95 CD O
% NN O
CI NN O
0.0001 CD O
, , O
0.014 CD O
) -RRB- O
in IN O
patients NNS O
with IN O
no DT O
LoF NNP O
alleles NNS O
at IN O
either DT O
of IN O
these DT O
genes NNS O
. . O

CONCLUSIONS NNS O
: : O
The DT O
presence NN O
of IN O
LoF IN O
allele(s NN O
) -RRB- O
at IN O
either DT O
CYP2B6 NNS B-Var
or CC O
CYP2C19 NNP B-Var
appeared VBD O
to TO O
result VB O
in IN O
decreased JJ B-NegReg
bioactivation NN B-MPA
of IN I-MPA
cyclophosphamide NN I-MPA
Mutant JJ O
p53 VBP O
R248Q ADD O
but CC O
not RB O
R248W NN O
enhances VBZ O
in IN O
vitro FW O
invasiveness NN O
of IN O
human JJ O
lung NN O
cancer NN O
NCI-H1299 NNP O
cells NNS O
. . O

More JJR O
than IN O
half NN O
of IN O
all DT O
human JJ B-Disease
cancers NNS I-Disease
are VBP O
associated VBN B-Reg
with IN O
mutations NNS B-Var
of IN O
the DT O
TP53 NNP B-Gene
gene NN O
. . O

In IN O
regard NN O
to IN O
the DT O
functional JJ O
interaction NN O
with IN O
the DT O
remaining VBG O
wild-type JJ O
( -LRB- O
WT NNP O
) -RRB- O
p53 NN O
allele NN O
, , O
p53 NN O
mutations NNS O
are VBP O
classified VBN O
into IN O
two CD O
types NNS O
, , O
recessive JJ O
and CC O
dominant-negative JJ B-Var
( -LRB- I-Var
DN NN I-Var
) -RRB- O
mutations NNS O
. . O

The DT O
latter JJ O
mutant JJ O
protein NN O
has VBZ O
a DT O
DN NN B-MPA
activity NN I-MPA
over IN B-PosReg
the DT I-PosReg
remaining VBG I-PosReg
WT NNP I-PosReg
allele NN I-PosReg
. . O

We PRP O
previously RB O
showed VBD O
that IN O
the DT O
DN NNP O
p53 NN O
mutant NN O
was VBD O
useful JJ O
as IN O
a DT O
predictor NN O
of IN O
poor JJ O
outcome NN O
or CC O
a DT O
risk NN O
factor NN O
for IN O
metastatic JJ O
recurrence NN O
in IN O
patients NNS O
with IN O
some DT O
types NNS O
of IN O
cancers NNS O
, , O
regardless RB O
of IN O
the DT O
presence NN O
or CC O
absence NN O
of IN O
loss NN O
of IN O
heterozygosity NN O
( -LRB- O
LOH NNP O
) -RRB- O
of IN O
WT NNP O
p53 NN O
, , O
suggesting VBG O
that IN O
the DT O
DN NNP B-Var
p53 NN B-Gene
had VBD O
' `` B-PosReg
gain-of-function VB I-PosReg
( -LRB- I-PosReg
GOF NN O
) -RRB- O
' POS O
activity NN O
besides IN O
the DT O
transdominance NN O
function NN O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
investigated VBD O
GOF NN O
activity NN O
of IN O
two CD O
DN NNP O
p53 NN O
mutants NNS O
which WDT O
had VBD O
a DT O
point NN O
mutation NN O
at IN O
codon VBN O
248 CD O
( -LRB- O
R248Q FW O
and CC O
R248W NNP O
) -RRB- O
, , O
one CD O
of IN O
the DT O
hot JJ O
spots NNS O
, , O
by IN O
transfecting VBG O
them PRP O
respectively RB O
into IN O
H1299 NNP O
cells NNS O
which WDT O
originally RB O
expressed VBD O
no DT O
p53 NN O
protein NN O
. . O

Growth NN O
activity NN O
of IN O
the DT O
transfectants NNS O
with IN O
the DT O
two CD O
mutants NNS O
was VBD O
not RB O
different JJ O
from IN O
that DT O
of IN O
parent NN O
or CC O
Mock NNP O
transfectants NNS O
. . O

Meanwhile RB O
, , O
in IN O
vitro FW B-CPA
invasions NNS I-CPA
of IN I-CPA
Matrigel NNP I-CPA
and CC I-CPA
type NN I-CPA
I PRP I-CPA
collagen NN I-CPA
gel NN I-CPA
by IN O
R248Q-transfectants NN B-Var
were VBD O
significantly RB O
higher JJR B-PosReg
Gain-of-function NN O
mutant JJ B-Var
p53 NN B-Gene
upregulates NNS B-PosReg
CXC NN B-MPA
chemokines NNS I-MPA
and CC O
enhances VBZ B-PosReg
cell NN B-CPA
migration NN I-CPA
. . O

The DT O
role NN O
of IN O
dominant JJ O
transforming VBG O
p53 NN O
in IN O
carcinogenesis NN O
is VBZ O
poorly RB O
understood VBN O
. . O

Our PRP$ O
previous JJ O
data NNS O
suggested VBD O
that IN O
aberrant NN B-Var
p53 NN B-Protein
proteins NNS I-Protein
can MD O
enhance VB B-PosReg
tumorigenesis NN B-CPA
and CC I-CPA
metastasis NN I-CPA
. . O

Here RB O
, , O
we PRP O
examined VBD O
potential JJ O
mechanisms NNS O
through IN O
which WDT O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
p53 NN O
proteins NNS O
can MD O
induce VB O
motility NN O
. . O

Cells NNS O
expressing VBG O
GOF NNP O
p53 NN B-Var
-R175H : I-Var
, , I-Var
-R273H : I-Var
and CC I-Var
-D281 : O
G NN O
showed VBD O
enhanced VBN B-PosReg
migration NN B-CPA
, , O
which WDT O
was VBD O
reversed VBN O
by IN O
RNA NNP O
interference NN O
( -LRB- O
RNAi NNPS O
) -RRB- O
or CC O
transactivation-deficient NN O
mutants NNS O
. . O

In IN O
cells NNS O
with IN O
engineered JJ O
or CC O
endogenous JJ O
p53 NN O
mutants NNS O
, , O
enhanced VBN O
migration NN O
was VBD O
reduced VBN O
by IN O
downregulation NN O
of IN O
nuclear JJ O
factor-kappaB2 NN O
, , O
a DT O
GOF NN O
p53 NN O
target NN O
. . O

We PRP O
found VBD O
that IN O
GOF NN B-Var
p53 NN I-Var
proteins NNS O
upregulate JJ B-PosReg
CXC-chemokine NN B-MPA
expression NN I-MPA
, , O
the DT O
inflammatory JJ O
mediators NNS O
that WDT O
contribute VBP O
to IN O
multiple JJ O
aspects NNS O
of IN O
tumorigenesis NN O
. . O

Elevated JJ B-PosReg
expression NN B-MPA
of IN O
CXCL5 NNP O
, , O
CXCL8 NN O
and CC O
CXCL12 NN O
was VBD O
found VBN O
in IN O
cells NNS O
expressing VBG O
oncogenic JJ B-Var
p53 NN I-Var
. . O

Transcription NN B-MPA
was VBD O
elevated VBN B-PosReg
as IN O
CXCL5 NNP B-MPA
and CC I-MPA
CXCL8 NNP I-MPA
promoter NN I-MPA
activity NN I-MPA
was VBD O
higher JJR B-PosReg
in IN O
cells NNS O
expressing VBG O
GOF NNP B-Var
p53 NN I-Var
, , O
whereas IN O
wild-type JJ O
p53 NN O
repressed VBN O
promoter NN O
activity NN O
. . O

Chromatin JJ O
immunoprecipitation NN O
assays NNS O
revealed VBD O
enhanced JJ O
presence NN O
of IN O
acetylated VBN O
histone NN O
H3 NNP O
on IN O
the DT O
CXCL5 NN O
promoter NN O
in IN O
H1299/R273H NNP O
cells NNS O
, , O
in IN O
agreement NN O
with IN O
increased VBN O
transcriptional JJ O
activity NN O
of IN O
the DT O
promoter NN O
, , O
whereas IN O
RNAi-mediated NNPS O
repression NN O
of IN O
CXCL5 NNP O
inhibited JJ O
cell NN O
migration NN O
. . O

Consistent JJ O
with IN O
this DT O
, , O
knockdown VBN O
of IN O
the DT O
endogenous JJ B-Var
mutant JJ I-Var
p53 NN B-Gene
in IN O
lung NN O
cancer NN O
or CC O
melanoma NN O
cells NNS O
reduced VBN B-NegReg
CXCL5 NN B-MPA
expression NN I-MPA
and CC O
cell NN B-CPA
migration NN I-CPA
. . O

Furthermore RB O
, , O
short JJ O
hairpin NN O
RNA NNP O
knockdown NN O
of IN O
mutant JJ B-Var
p53 NN B-Gene
in IN O
MDA-MB-231 NNP O
cells NNS O
reduced VBD B-NegReg
expression NN B-MPA
of IN I-MPA
a DT I-MPA
number NN I-MPA
of IN I-MPA
key JJ I-MPA
targets NNS I-MPA
, , O
including VBG O
several JJ O
chemokines NNS O
and CC O
other JJ O
inflammatory JJ O
mediators NNS O
. . O

Finally RB O
, , O
CXCL5 NN B-MPA
expression NN I-MPA
was VBD O
also RB O
elevated VBN B-PosReg
in IN O
lung NN B-Disease
tumor NN I-Disease
samples NNS O
containing VBG O
GOF NNP B-Var
p53 NN I-Var
Allele NNP O
specific JJ O
gain-of-function NN B-PosReg
activity NN B-MPA
of IN O
p53 NN B-Gene
mutants NNS B-Var
in IN O
lung NN B-Disease
cancer NN I-Disease
cells NNS O
. . O

p53 NN B-Gene
mutations NNS B-Var
are VBP O
mostly RB O
single JJ O
amino NN O
acid NN O
changes NNS O
resulting VBG B-Reg
in IN I-Reg
expression NN B-MPA
of IN O
a DT O
stable JJ O
mutant JJ O
protein NN O
with IN O
" `` O
gain NN B-PosReg
of IN I-PosReg
function NN I-PosReg
" '' O
( -LRB- O
GOF NN O
) -RRB- O
activity NN B-MPA
having VBG O
a DT O
dominant JJ O
oncogenic JJ O
role NN O
rather RB O
than IN O
simple JJ O
loss NN O
of IN O
function NN O
of IN O
wild-type JJ O
p53 NN O
. . O

Knock-down NNP O
of IN O
mutant JJ O
p53 NN O
in IN O
human JJ O
lung NN O
cancer NN O
cell NN O
lines NNS O
with IN O
different JJ O
endogenous JJ O
p53 NN B-Gene
mutants NNS B-Var
results NNS O
in IN O
loss NN B-NegReg
of IN O
GOF NN O
activity NN B-MPA
as IN O
shown VBN O
by IN O
lowering VBG B-NegReg
of IN O
cell NN B-CPA
growth NN I-CPA
rate NN I-CPA
. . O

Two CD O
lung NN O
cancer NN O
cell NN O
lines NNS O
, , O
ABC1 NNP O
and CC O
H1437 NNP O
, , O
carrying VBG O
endogenous JJ O
mutants NNS B-Var
p53-P278S NNS I-Var
and CC I-Var
-R267P : I-Var
, , O
show VBP O
reduction NN B-NegReg
in IN O
growth NN B-MPA
rate NN I-MPA
on IN O
knock-down VB O
on IN O
p53 NN O
levels NNS O
. . O

However RB O
, , O
whereas IN O
reduction NN B-NegReg
of IN O
the DT O
p53 NN B-Var
level NN O
induces VBZ O
loss NN B-NegReg
of IN O
tumorigenicity NN B-MPA
in IN O
nude JJ O
mice NNS O
for IN O
ABC1 NNP O
cells NNS O
, , O
it PRP O
escalates VBZ B-PosReg
tumorigenicity NN B-MPA
Gain-of-Function NN O
Activity NNP O
of IN O
Mutant NNP O
p53 NN O
in IN O
Lung NNP O
Cancer NNP O
through IN O
Up-Regulation NNP O
of IN O
Receptor NNP O
Protein NNP O
Tyrosine NNP O
Kinase NNP O
Axl NNP O
. . O

p53 NN O
mutations NNS O
are VBP O
present JJ O
in IN O
up IN O
to TO O
70 CD O
% NN O
of IN O
lung NN O
cancer NN O
. . O

Cancer NN O
cells NNS O
with IN O
p53 NN B-Gene
mutations NNS B-Var
, , O
in IN O
general JJ O
, , O
grow VB B-CPA
more RBR O
aggressively RB B-PosReg
than IN O
those DT O
with IN O
wild-type JJ O
p53 NN O
or CC O
no DT O
p53 NN O
. . O

Expression NN O
of IN O
tumor-derived NN O
mutant JJ B-Var
p53 NN B-Gene
in IN O
cells NNS O
leads VBZ O
to IN O
up-regulated RB B-PosReg
expression NN B-MPA
of IN I-MPA
genes NNS I-MPA
that WDT O
may MD O
affect VB B-Reg
cell NN B-CPA
growth NN I-CPA
and CC O
oncogenesis NN B-CPA
. . O

In IN O
our PRP$ O
study NN O
of IN O
this DT O
aggressive JJ O
phenotype NN O
, , O
we PRP O
have VBP O
investigated VBN O
the DT O
receptor NN O
protein NN O
tyrosine NN B-Enzyme
kinase NN I-Enzyme
Axl NNP I-Enzyme
, , O
which WDT O
is VBZ O
up-regulated RB B-PosReg
by IN O
p53 NN B-Gene
mutants NNS B-Var
at IN O
both CC O
RNA NNP O
and CC O
protein NN O
levels NNS O
in IN O
H1299 NNP O
lung NN O
cancer NN O
cells NNS O
expressing VBG O
mutants NNS O
p53-R175H NNS O
, , O
-R273H : O
, , O
and CC O
-D281G. NFP O
Knockdown NNP O
of IN O
endogenous JJ O
mutant JJ O
p53 NN O
levels NNS O
in IN O
human JJ O
lung NN O
cancer NN O
cells NNS O
H1048 NNP O
( -LRB- O
p53-R273C NNP O
) -RRB- O
and CC O
H1437 NNP O
( -LRB- O
p53-R267P NNP O
) -RRB- O
led VBD O
to IN O
a DT O
reduction NN O
in IN O
the DT O
level NN O
of IN O
Axl NNP O
as RB O
well RB O
. . O

This DT O
effect NN O
on IN O
Axl NNP O
expression NN O
is VBZ O
refractory JJ O
to IN O
the DT O
mutations NNS O
at IN O
positions NNS O
22 CD O
and CC O
23 CD O
of IN O
p53 NN O
, , O
suggesting VBG O
that IN O
p53 NN O
's POS O
transactivation NN O
domain NN O
may MD O
not RB O
play VB O
a DT O
critical JJ O
role NN O
in IN O
the DT O
up-regulation NN O
of IN O
Axl NNP O
gene NN O
expression NN O
. . O

Chromatin JJ O
immunoprecipitation NN O
( -LRB- O
ChIP NN O
) -RRB- O
assays NNS O
carried VBD O
out RP O
with IN O
acetylated JJ O
histone NN O
antibodies NNS O
demonstrated VBD O
induced VBN O
histone NN B-Reg
acetylation NN B-MPA
on IN I-MPA
the DT I-MPA
Axl NNP I-MPA
promoter NN I-MPA
region NN I-MPA
by IN O
mutant JJ B-Var
p53 NN B-Gene
. . O

Direct JJ O
mutant JJ O
p53 NN O
nucleation NN O
on IN O
the DT O
Axl NNP O
promoter NN O
was VBD O
demonstrated VBN O
by IN O
ChIP NN O
assays NNS O
using VBG O
antibodies NNS O
against IN O
p53 NN O
. . O

The DT O
Axl NNP O
promoter NN O
has VBZ O
a DT O
p53/p63 NN O
binding VBG O
site NN O
, , O
which WDT O
however RB O
is VBZ O
not RB O
required VBN O
for IN O
mutant JJ O
p53-mediated VBN O
transactivation NN O
. . O

Knockdown NNP O
of IN O
Axl NNP O
by IN O
Axl-specific NNP O
RNAi NNPS O
caused VBD O
a DT O
reduction NN O
of IN O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
activities NNS O
, , O
reducing VBG O
the DT O
cell NN O
growth NN O
rate NN O
and CC O
motility NN O
rate NN O
in IN O
lung NN O
cancer NN O
cells NNS O
expressing VBG O
mutant JJ O
p53 NN O
. . O

This DT O
indicates VBZ O
that IN O
for IN O
lung NN O
cancer NN O
cell NN O
lines NNS O
with IN O
mutant JJ B-Var
p53 NN B-Gene
, , O
GOF NN O
activities NNS B-MPA
are VBP O
mediated VBN B-Reg
in IN O
part NN O
through IN O
Axl NNP B-Protein
Gain-of-function NN O
mutations NNS O
in IN O
PDR1 NNP O
, , O
a DT O
regulator NN O
of IN O
antifungal JJ O
drug NN O
resistance NN O
in IN O
Candida NNP O
glabrata NN O
, , O
control NN O
adherence NN O
to IN O
host NN O
cells NNS O
. . O

Candida NNP O
glabrata NN O
is VBZ O
an DT O
emerging VBG O
opportunistic JJ O
pathogen NN O
that WDT O
is VBZ O
known VBN O
to TO O
develop VB O
resistance NN O
to IN O
azole VB O
drugs NNS O
due JJ O
to IN O
increased VBN O
drug NN O
efflux NN O
. . O

The DT O
mechanism NN O
consists VBZ O
of IN O
CgPDR1-mediated JJ O
upregulation NN O
of IN O
ATP-binding NNP O
cassette NN O
transporters NNS O
. . O

A DT O
range NN O
of IN O
gain-of-function NN B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
in IN O
CgPDR1 NN B-Gene
have VBP O
been VBN O
found VBN O
to TO O
lead VB B-PosReg
not RB O
only RB O
to TO O
azole VB B-MPA
resistance NN I-MPA
but CC O
also RB O
to IN O
enhanced VBN B-PosReg
virulence NN B-MPA
. . O

This DT O
implicates VBZ B-Reg
CgPDR1 VBP B-Gene
in IN O
the DT O
regulation NN B-MPA
of IN O
the DT O
interaction NN B-Interaction
of IN O
C. NNP O
glabrata NN O
with IN O
the DT O
host NN O
. . O

To TO O
identify VB O
specific JJ O
CgPDR1-regulated JJ O
steps NNS O
of IN O
the DT O
host-pathogen NN O
interaction NN O
, , O
we PRP O
investigated VBD O
in IN O
this DT O
work NN O
the DT O
interaction NN O
of IN O
selected VBN O
CgPDR1 NNP O
GOF NNP O
mutants NNS O
with IN O
murine NN O
bone NN O
marrow-derived NN O
macrophages NNS O
and CC O
human JJ O
acute NN O
monocytic JJ O
leukemia NN O
cell NN O
line NN O
( -LRB- O
THP-1)-derived VBN O
macrophages NNS O
, , O
as RB O
well RB O
as IN O
different JJ O
epithelial JJ O
cell NN O
lines NNS O
. . O

GOF NN O
mutations NNS B-Var
in IN O
CgPDR1 NN B-Gene
did VBD O
not RB O
influence VB O
survival NN O
and CC O
replication NN O
within IN O
macrophages NNS O
following VBG O
phagocytosis NN O
but CC O
led VBD O
to IN O
decreased VBN B-NegReg
adherence NN B-CPA
to IN I-CPA
and CC I-CPA
uptake VB I-CPA
by IN I-CPA
macrophages NNS I-CPA
. . O

This DT O
may MD O
allow VB O
evasion NN O
from IN O
the DT O
host NN O
's POS O
innate JJ O
cellular JJ O
immune JJ O
response NN O
. . O

The DT O
interaction NN O
with IN O
epithelial JJ O
cells NNS O
revealed VBD O
an DT O
opposite JJ O
trend NN O
, , O
suggesting VBG O
that IN O
GOF NN O
mutations NNS B-Var
in IN O
CgPDR1 NN B-Gene
may MD O
favor VB B-PosReg
epithelial JJ B-CPA
colonization NN I-CPA
of IN O
the DT O
host NN O
by IN O
C. NNP O
glabrata NN O
through IN O
increased VBN B-PosReg
adherence NN B-CPA
to IN O
epithelial JJ O
cell NN O
layers NNS O
. . O

These DT O
data NNS O
reveal VBP O
that IN O
GOF NN O
mutations NNS B-Var
in IN O
CgPDR1 NN B-Gene
modulate VBP B-Reg
the DT O
interaction NN B-Interaction
with IN O
host NN O
cells NNS O
in IN O
ways NNS O
that WDT O
may MD O
contribute VB O
to IN O
increased VBN B-PosReg
virulence NN B-MPA
Mutant JJ O
p53 NN O
prolongs NNS O
activation NN O
and CC O
promotes VBZ O
chronic JJ O
inflammation NN O
and CC O
inflammation-associated NN O
colorectal NN O
cancer NN O
. . O

The DT O
tumor NN O
suppressor NN O
p53 NN O
is VBZ O
frequently RB O
mutated VBN O
in IN O
human JJ O
cancer NN O
. . O

Common JJ O
mutant JJ O
p53 NN O
( -LRB- O
mutp53 NN O
) -RRB- O
isoforms NNS O
can MD O
actively RB O
promote VB O
cancer NN O
through IN O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
mechanisms NNS O
. . O

We PRP O
report VBP O
that IN O
mutp53 NN O
prolongs NNS O
activation NN O
in IN O
cultured JJ O
cells NNS O
and CC O
intestinal JJ O
organoid NN O
cultures NNS O
. . O

Remarkably RB O
, , O
when WRB O
exposed VBN O
to IN O
dextran JJ O
sulfate NN O
sodium NN O
, , O
mice NNS O
harboring VBG O
a DT O
germline NN O
p53 NN O
mutation NN O
develop VB O
severe JJ O
chronic JJ O
inflammation NN O
and CC O
persistent JJ O
tissue NN O
damage NN O
, , O
and CC O
are VBP O
highly RB O
prone JJ O
to IN O
inflammation-associated NN O
colon NN O
cancer NN O
. . O

This DT O
mutp53 NN O
GOF NNP O
is VBZ O
manifested VBN O
by IN O
rapid JJ O
onset NN O
of IN O
flat JJ O
dysplastic JJ O
lesions NNS O
that WDT O
progress VBP B-PosReg
to IN O
invasive JJ B-Disease
carcinoma NN I-Disease
with IN O
mutp53 NN B-Var
accumulation NN B-PosReg
and CC O
augmented VBN O
activation NN B-PosReg
, , O
faithfully RB O
recapitulating VBG O
features NNS O
frequently RB O
observed VBN O
in IN O
human JJ O
colitis-associated NN B-Disease
colorectal NN I-Disease
cancer NN I-Disease
Clinical JJ O
relevance NN O
of IN O
gain-of-function NN B-PosReg
mutations NNS B-Var
of IN O
p53 NN B-Gene
in IN O
high-grade JJ B-Disease
serous JJ I-Disease
ovarian JJ I-Disease
carcinoma NN I-Disease
. . O

PURPOSE NNP O
: : O
Inactivation NNP O
of IN O
TP53 NNP O
, , O
which WDT O
occurs VBZ O
predominantly RB O
by IN O
missense NN O
mutations NNS O
in IN O
exons NNS O
4-9 CD O
, , O
is VBZ O
a DT O
major JJ O
genetic JJ O
alteration NN O
in IN O
a DT O
subset NN O
of IN O
human JJ O
cancer NN O
. . O

In IN O
spite NN O
of IN O
growing VBG O
evidence NN O
that IN O
gain-of-function VB B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
of IN O
p53 NN B-Gene
also RB O
have VB O
oncogenic JJ B-CPA
activity NN I-CPA
, , O
little JJ O
is VBZ O
known VBN O
about IN O
the DT O
clinical JJ O
relevance NN O
of IN O
these DT O
mutations NNS O
. . O

METHODS NNS O
: : O
The DT O
clinicopathological JJ O
features NNS O
of IN O
high-grade JJ O
serous JJ O
ovarian JJ O
carcinoma NN O
( -LRB- O
HGS-OvCa NNP O
) -RRB- O
patients NNS O
with IN O
GOF NNP O
p53 NN O
mutations NNS O
were VBD O
evaluated VBN O
according VBG O
to IN O
a DT O
comprehensive JJ O
somatic JJ O
mutation NN O
profile NN O
comprised VBN O
of IN O
whole JJ O
exome JJ O
sequencing NN O
, , O
mRNA NNS O
expression NN O
, , O
and CC O
protein NN O
expression NN O
profiles NNS O
obtained VBN O
from IN O
the DT O
Cancer NNP O
Genome NNP O
Atlas NNP O
( -LRB- O
TCGA NNP O
) -RRB- O
. . O

RESULTS NNP O
: : O
Patients NNS O
with IN O
a DT O
mutant JJ O
p53 NN B-Protein
protein NN I-Protein
( -LRB- O
mutp53 NN O
) -RRB- O
with IN O
a DT O
GOF NN O
mutation NN B-Var
showed VBD O
higher JJR B-PosReg
p53 NN B-MPA
mRNA NNS I-MPA
and CC I-MPA
protein NN I-MPA
expression NN I-MPA
levels NNS I-MPA
than IN O
patients NNS O
with IN O
p53 NN O
mutation NN O
with IN O
no DT O
evidence NN O
of IN O
GOF NNP O
( -LRB- O
NE-GOF NNP O
) -RRB- O
. . O

GOF NN O
mutations NNS O
were VBD O
more RBR O
likely JJ O
to TO O
occur VB O
within IN O
mutational JJ O
hotspots NNS O
, , O
and CC O
at IN O
CpG NNP O
sites NNS O
, , O
and CC O
resulted VBD O
in IN O
mutp53 NN O
with IN O
higher JJR O
functional JJ O
severity NN O
( -LRB- O
FS NN O
) -RRB- O
scores NNS O
. . O

Clinically RB O
, , O
patients NNS O
with IN O
GOF NN O
mutations NNS B-Var
showed VBD O
a DT O
higher JJR B-PosReg
frequency NN O
of IN O
platinum NN B-CPA
resistance NN I-CPA
( -LRB- O
22/58 CD O
, , O
37.9 CD O
% NN O
) -RRB- O
than IN O
patients NNS O
with IN O
NE-GOF NNP O
mutations NNS O
( -LRB- O
12/56 CD O
, , O
21.4 CD O
% NN O
) -RRB- O
( -LRB- O
p=0.054 NNP O
) -RRB- O
. . O

Furthermore RB O
, , O
patients NNS O
with IN O
GOF NN O
mutations NNS B-Var
were VBD O
more RBR O
likely JJ O
to TO O
develop VB B-PosReg
distant JJ B-CPA
metastasis NN I-CPA
( -LRB- O
36/55 CD O
, , O
65.5 CD O
% NN O
) -RRB- O
than IN O
local JJ O
recurrence NN O
( -LRB- O
19/55 CD O
, , O
34.5 CD O
% NN O
) -RRB- O
, , O
whereas IN O
patients NNS O
with IN O
NE-GOF NNP O
mutations NNS O
showed VBD O
a DT O
higher JJR O
frequency NN O
of IN O
locoregional JJ O
recurrence NN O
( -LRB- O
26/47 CD O
, , O
55.3 CD O
% NN O
) -RRB- O
than IN O
distant JJ O
metastasis NN O
( -LRB- O
21/47 CD O
, , O
44.7 CD O
% NN O
) -RRB- O
( -LRB- O
p=0.035 NNP O
) -RRB- O
. . O

There EX O
were VBD O
no DT O
differences NNS O
in IN O
overall JJ O
or CC O
progression-free NN O
survival NN O
between IN O
patients NNS O
with IN O
GOF NNP O
or CC O
NE-GOF NNP O
mutp53 NN O
. . O

CONCLUSION NN O
: : O
This DT O
study NN O
demonstrates VBZ O
that DT O
patient JJ O
with IN O
GOF NN B-PosReg
mutp53 NN B-Var
is VBZ O
characterized VBN O
by IN O
a DT O
greater JJR B-PosReg
likelihood NN O
of IN O
platinum NN B-CPA
treatment NN I-CPA
resistance NN I-CPA
and CC O
distant JJ B-CPA
metastatic JJ I-CPA
properties NNS I-CPA
in IN O
HGS-OvCa NNP B-Disease
Spliced JJ O
MDM2 JJ O
isoforms NNS O
promote VBP O
mutant JJ O
p53 NN O
accumulation NN O
and CC O
gain-of-function VB O
in IN O
tumorigenesis NN O
. . O

The DT O
tumour NN O
suppressor NN O
p53 NN O
is VBZ O
frequently RB O
mutated VBN O
in IN O
tumours NNS O
. . O

Mutant JJ B-Var
p53 NN B-Protein
( -LRB- O
Mutp53 NN O
) -RRB- O
proteins NNS O
often RB O
gain VBP B-PosReg
new JJ I-PosReg
activities NNS I-PosReg
in IN O
promoting VBG B-CPA
tumorigenesis NN I-CPA
, , O
defined VBN O
as IN O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
. . O

Mutp53 NN O
can MD O
accumulate VB O
to IN O
high JJ O
levels NNS O
in IN O
tumours NNS O
, , O
which WDT O
promotes VBZ O
mutp53 NN B-Var
GOF NN B-PosReg
in IN O
tumorigenesis NN B-CPA
. . O

The DT O
mechanism NN O
of IN O
mutp53 NN O
accumulation NN O
is VBZ O
poorly RB O
understood VBN O
. . O

Here RB O
we PRP O
find VBP O
that IN O
MDM2 JJ O
isoforms NNS O
promote VBP O
mutp53 NN O
accumulation NN O
in IN O
tumours NNS O
. . O

MDM2 JJ O
isoform NN O
B NNP O
( -LRB- O
MDM2-B NNP O
) -RRB- O
, , O
the DT O
MDM2 NNP O
isoform NN O
most RBS O
frequently RB O
over-expressed RB O
in IN O
human JJ O
tumours NNS O
, , O
interacts VBZ O
with IN O
full-length JJ O
MDM2 NNP O
to TO O
inhibit VB O
MDM2-mediated VBD O
mutp53 NN O
degradation NN O
, , O
promoting VBG O
mutp53 NN O
accumulation NN O
and CC O
GOF NN O
in IN O
tumorigenesis NN O
. . O

Furthermore RB O
, , O
MDM2-B CD O
overexpression NN O
correlates VBZ O
with IN O
mutp53 NN O
accumulation NN O
in IN O
human JJ O
tumours NNS O
. . O

In IN O
mutp53 NN O
knock-in VB O
mice NNS O
, , O
a DT O
MDM2 NNP O
isoform NN O
similar JJ O
to IN O
human JJ O
MDM2-B CD O
is VBZ O
overexpressed VBN O
in IN O
the DT O
majority NN O
of IN O
tumours NNS O
, , O
which WDT O
promotes VBZ O
mutp53 NN O
accumulation NN O
and CC O
tumorigenesis NN O
. . O

Thus RB O
, , O
overexpression NN O
of IN O
MDM2 NNP O
isoforms NNS O
promotes VBZ O
mutp53 NN O
accumulation NN O
in IN O
tumours NNS O
, , O
contributing VBG O
to IN O
mutp53 NN B-Var
GOF NN B-PosReg
in IN O
tumorigenesis NN B-CPA
Mutant JJ B-Var
p53 VBP B-Gene
gain NN B-PosReg
of IN I-PosReg
function NN I-PosReg
can MD O
be VB O
at IN O
the DT O
root NN O
of IN O
dedifferentiation NN O
of IN O
human JJ B-Disease
osteosarcoma NN I-Disease
MG63 NNP O
cells NNS O
into IN O
3AB-OS JJ O
cancer NN O
stem NN O
cells NNS O
. . O

Osteosarcoma NNP O
is VBZ O
a DT O
highly RB O
metastatic JJ O
tumor NN O
affecting VBG O
adolescents NNS O
, , O
for IN O
which WDT O
there EX O
is VBZ O
no DT O
second-line JJ O
chemotherapy NN O
. . O

As IN O
suggested VBN O
for IN O
most JJS O
tumors NNS O
, , O
its PRP$ O
capability NN O
to TO O
overgrow VB O
is VBZ O
probably RB O
driven VBN O
by IN O
cancer NN O
stem NN O
cells NNS O
( -LRB- O
CSCs NNPS O
) -RRB- O
, , O
and CC O
finding VBG O
new JJ O
targets NNS O
to TO O
kill VB O
CSCs NNS O
may MD O
be VB O
critical JJ O
for IN O
improving VBG O
patient JJ O
survival NN O
. . O

TP53 NNP O
is VBZ O
the DT O
most RBS O
frequently RB O
mutated VBN O
tumor NN O
suppressor NN O
gene NN O
in IN O
cancers NNS O
and CC O
mutant JJ O
p53 NN O
protein NN O
( -LRB- O
mutp53 NN O
) -RRB- O
can MD O
acquire VB O
gain NN O
of IN O
function NN O
( -LRB- O
GOF NN O
) -RRB- O
strongly RB O
contributing VBG O
to IN O
malignancy NN O
. . O

Studies NNS O
thus RB O
far RB O
have VBP O
not RB O
shown VBN O
p53-GOF NN O
in IN O
osteosarcoma NN O
. . O

Here RB O
, , O
we PRP O
investigated VBD O
TP53 NNP O
gene NN O
status NN O
/ SYM O
role NN O
in IN O
3AB-OS JJ O
cells-a NNS O
highly RB O
aggressive JJ O
CSC NNP O
line NN O
previously RB O
selected VBN O
from IN O
human JJ O
osteosarcoma NN O
MG63 NNP O
cells-to NNS O
evaluate VB O
its PRP$ O
involvement NN O
in IN O
promoting VBG O
proliferation NN O
, , O
invasiveness NN O
, , O
resistance NN O
to IN O
apoptosis NN O
and CC O
stemness NN O
. . O

By IN O
RT-PCR NNP O
, , O
methylation-specific NN O
PCR NNP O
, , O
fluorescent JJ O
in IN O
situ NN O
hybridization NN O
, , O
DNA NN O
sequence NN O
, , O
western JJ O
blot NN O
and CC O
immunofluorescence VB O
analyses NNS O
, , O
we PRP O
have VBP O
shown VBN O
that-in IN O
comparison NN O
with IN O
parental JJ O
MG63 NNP O
cells NNS O
where WRB O
TP53 NNP O
gene NN O
is VBZ O
hypermethylated VBN O
, , O
rearranged VBN O
and CC O
in IN O
single JJ O
copy-in NN O
3AB-OS JJ O
cells NNS O
, , O
TP53 NNP O
is VBZ O
unmethylated JJ O
, , O
rearranged VBN O
and CC O
in IN O
multiple JJ O
copies NNS O
, , O
and CC O
mutp53 NN O
( -LRB- O
p53-R248W NNP O
/ SYM O
P72R NNP O
) -RRB- O
is VBZ O
post-translationally NN O
modified VBN O
and CC O
with IN O
nuclear JJ O
localization NN O
. . O

p53-R248W NNP O
/ SYM O
P72R-knockdown NNP O
by IN O
short-interfering RB O
RNA NNP O
reduced VBD O
the DT O
growth NN O
and CC O
replication NN O
rate NN O
of IN O
3AB-OS JJ O
cells NNS O
, , O
markedly RB O
increasing VBG O
cell NN O
cycle NN O
inhibitor NN O
levels NNS O
and CC O
sensitized VBN O
3AB-OS JJ O
cells NNS O
to IN O
TRAIL-induced NN O
apoptosis NN O
by IN O
DR5 NNP O
up-regulation RP O
; : O
moreover RB O
, , O
it PRP O
strongly RB O
decreased VBD O
the DT O
levels NNS O
of IN O
stemness NN O
and CC O
invasiveness NN O
genes NNS O
. . O

We PRP O
have VBP O
also RB O
found VBN O
that IN O
the DT O
ectopic JJ O
expression NN O
of IN O
p53-R248W NNP B-Var
/ SYM O
P72R NNP O
in IN O
MG63 NNP O
cells NNS O
promoted VBD B-PosReg
cancer NN B-CPA
stem-like NN I-CPA
features NNS I-CPA
, , O
as IN O
high JJ B-CPA
proliferation NN I-CPA
rate NN I-CPA
, , O
sphere NN B-CPA
formation NN I-CPA
, , O
clonogenic JJ B-CPA
growth NN I-CPA
, , O
high JJ B-CPA
migration NN I-CPA
and CC O
invasive JJ B-CPA
ability NN I-CPA
; : O
furthermore RB O
, , O
it PRP O
strongly RB O
increased VBD B-PosReg
the DT O
levels NNS B-MPA
of IN I-MPA
stemness NN I-MPA
proteins NNS I-MPA
. . O

Overall RB O
, , O
the DT O
findings NNS O
suggest VBP O
the DT O
involvement NN B-Reg
of IN O
p53-R248W NNP B-Var
/ SYM O
P72R NNP O
at IN O
the DT O
origin NN B-CPA
of IN I-CPA
the DT I-CPA
aberrant NN I-CPA
characters NNS I-CPA
of IN I-CPA
the DT I-CPA
3AB-OS JJ I-CPA
cells NNS I-CPA
Unequal JJ O
prognostic JJ O
potentials NNS O
of IN O
p53 NN O
gain-of-function JJ O
mutations NNS O
in IN O
human JJ O
cancers NNS O
associate JJ O
with IN O
drug-metabolizing NN O
activity NN O
. . O

Mutation NNP O
of IN O
p53 NN O
is VBZ O
the DT O
most RBS O
common JJ O
genetic JJ O
change NN O
in IN O
human JJ O
cancer NN O
, , O
causing VBG O
complex JJ O
effects NNS O
including VBG O
not RB O
only RB O
loss NN O
of IN O
wild-type JJ O
function NN O
but CC O
also RB O
gain NN O
of IN O
novel JJ O
oncogenic JJ O
functions NNS O
( -LRB- O
GOF NN O
) -RRB- O
. . O

It PRP O
is VBZ O
increasingly RB O
likely JJ O
that IN O
p53-hotspot JJ O
mutations NNS O
may MD O
confer VB O
different JJ O
types NNS O
and CC O
magnitudes NNS O
of IN O
GOF NN O
, , O
but CC O
the DT O
evidences NNS O
are VBP O
mainly RB O
supported VBN O
by IN O
cellular JJ O
and CC O
transgenic JJ O
animal NN O
models NNS O
. . O

Here RB O
we PRP O
combine VBP O
large-scale JJ O
cancer NN O
genomic NN O
data NNS O
to TO O
characterize VB O
the DT O
prognostic JJ O
significance NN O
of IN O
different JJ O
p53 NN B-Gene
mutations NNS O
in IN O
human JJ O
cancers NNS O
. . O

Unexpectedly RB O
, , O
only RB O
mutations NNS B-Var
on IN I-Var
the DT I-Var
Arg248 NN I-Var
and CC I-Var
Arg282 NN I-Var
positions NNS O
displayed VBD O
significant JJ O
association NN O
with IN O
shorter JJR B-NegReg
patient JJ B-CPA
survival NN I-CPA
, , O
but CC O
such JJ O
association NN O
was VBD O
not RB O
evident JJ O
for IN O
other JJ O
hotspot JJ O
GOF NN O
mutations NNS O
. . O

Gene NN O
set VBD O
enrichment NN O
analysis NN O
on IN O
these DT O
mutations NNS B-Var
revealed VBD O
higher JJR B-PosReg
activity NN B-MPA
of IN O
drug-metabolizing NN B-Enzyme
enzymes NNS I-Enzyme
, , O
including VBG O
the DT O
CYP3A4 NNP B-Enzyme
cytochrome NN I-Enzyme
P450 NNP I-Enzyme
. . O

Ectopic JJ B-MPA
expression NN I-MPA
of IN O
p53 NN B-Gene
mutant JJ B-Var
R282W NN I-Var
in IN O
H1299 NNP O
and CC O
SaOS2 NN O
cells NNS O
significantly RB O
upregulated JJ B-PosReg
CYP3A4 NNP B-MPA
mRNA NNS I-MPA
and CC I-MPA
protein NN I-MPA
levels NNS I-MPA
, , O
and CC O
cancer NN O
cell NN O
lines NNS O
bearing VBG O
mortality-associated NN O
p53 NN B-Gene
mutations NNS B-Var
display VBP O
higher JJR B-PosReg
CYP3A4 NNP B-Enzyme
expression NN B-MPA
and CC O
resistance NN B-CPA
to IN I-CPA
several JJ I-CPA
CYP3A4-metabolized JJ I-CPA
chemotherapeutic JJ I-CPA
drugs NNS I-CPA
Disruption NN O
of IN O
the DT O
temporally RB O
regulated JJ O
cloaca NNS O
endodermal NN O
signaling NN O
causes VBZ O
anorectal JJ O
malformations NNS O
. . O

The DT O
cloaca NNS O
is VBZ O
temporally RB O
formed VBN O
and CC O
eventually RB O
divided VBN O
by IN O
the DT O
urorectal JJ O
septum NN O
( -LRB- O
URS NNP O
) -RRB- O
during IN O
urogenital JJ O
and CC O
anorectal JJ O
organ NN O
development NN O
. . O

Although IN O
congenital JJ O
malformations NNS O
, , O
such JJ O
as IN O
anorectal JJ O
malformations NNS O
( -LRB- O
ARMs NNPS O
) -RRB- O
, , O
are VBP O
frequently RB O
observed VBN O
during IN O
this DT O
process NN O
, , O
the DT O
underlying JJ O
pathogenic JJ O
mechanisms NNS O
remain VBP O
unclear JJ O
. . O

is VBZ O
a DT O
critical JJ O
component NN O
of IN O
canonical JJ O
Wnt NNP O
signaling VBG O
and CC O
is VBZ O
essential JJ O
for IN O
the DT O
regulation NN O
of IN O
cell NN O
differentiation NN O
and CC O
morphogenesis NN O
during IN O
embryogenesis NN O
. . O

The DT O
expression NN O
of IN O
is VBZ O
observed VBN O
in IN O
endodermal JJ O
epithelia NN O
, , O
including VBG O
URS NNP O
epithelia NN O
. . O

We PRP O
modulated VBD O
the DT O
gene NN O
conditionally RB O
in IN O
endodermal JJ O
epithelia NN O
by IN O
utilizing VBG O
tamoxifen-inducible RB O
Cre NNP O
driver NN O
line NN O
( -LRB- O
Shh(CreERT2 NNP O
) -RRB- O
) -RRB- O
. . O

Both DT O
loss- VBD B-NegReg
and CC O
gain-of-function VB B-PosReg
( -LRB- O
LOF NNP O
and CC O
GOF NN O
) -RRB- O
mutants NNS B-Var
displayed VBD O
abnormal JJ O
clefts NNS B-CPA
in IN I-CPA
the DT I-CPA
perineal NN I-CPA
region NN I-CPA
and CC O
hypoplastic JJ B-CPA
elongation NN I-CPA
of IN I-CPA
the DT I-CPA
URS NNP I-CPA
. . O

The DT O
mutants NNS B-Var
also RB O
displayed VBD O
reduced JJ B-NegReg
cell NN B-CPA
proliferation NN I-CPA
in IN I-CPA
the DT I-CPA
URS NNP I-CPA
mesenchyme NN I-CPA
. . O

In IN O
addition NN O
, , O
the DT O
GOF NNP O
mutants NNS B-Var
displayed VBD O
reduced JJ O
apoptosis NN O
and CC O
subsequently RB O
increased VBN O
apoptosis NN O
in IN O
the DT O
URS NNP O
epithelium NN O
. . O

This DT O
instability NN O
possibly RB O
resulted VBD O
in IN O
reduced JJ B-NegReg
expression NN B-MPA
levels NNS I-MPA
of IN O
differentiation NN O
markers NNS O
, , O
such JJ O
as IN O
keratin NN B-Protein
1 CD I-Protein
and CC O
filaggrin NN B-Protein
, , O
in IN O
the DT O
perineal NN O
epithelia NN O
. . O

The DT O
expression NN B-MPA
of IN O
bone NN B-Gene
morphogenetic JJ I-Gene
protein NN I-Gene
( -LRB- I-Gene
Bmp NNP I-Gene
) -RRB- O
genes NNS O
, , O
such JJ O
as IN O
Bmp4 JJ B-Gene
and CC O
Bmp7 NN B-Gene
, , O
was VBD O
also RB O
ectopically RB O
induced VBN B-PosReg
in IN O
the DT O
epithelia NN O
of IN O
the DT O
URS NNP O
in IN O
the DT O
GOF NNP O
mutants NNS B-Var
. . O

The DT O
expression NN B-MPA
of IN O
the DT O
Msx2 JJ B-Gene
gene NN I-Gene
and CC O
phosphorylated-Smad1/5/8 VBN O
, , O
possible JJ O
readouts NNS B-MPA
of IN I-MPA
Bmp NNP I-MPA
signaling NN I-MPA
, , O
was VBD O
also RB O
increased VBN B-PosReg
in IN O
the DT O
mutants NNS B-Var
. . O

Moreover RB O
, , O
we PRP O
introduced VBD O
an DT O
additional JJ O
mutation NN O
for IN O
a DT O
Bmp NNP O
receptor NN O
gene NN O
: : O
BmprIA NNP O
. . O

The DT O
Shh(CreERT2/+ NNP O
) -RRB- O
; : O
) -RRB- O
; : O
BmprIA(flox/- RB O
) -RRB- O
mutants NNS O
displayed VBD O
partial JJ O
restoration NN O
of IN O
URS NNP O
elongation NN O
compared VBN O
with IN O
the DT O
GOF NNP O
mutants NNS O
. . O

These DT O
results NNS O
indicate VBP O
that IN O
some DT O
ARM NNP B-Disease
phenotypes NNS O
in IN O
the DT O
GOF NNP B-PosReg
mutants NNS B-Var
were VBD O
caused VBN B-Reg
by IN I-Reg
abnormal JJ O
Bmp NNP B-MPA
signaling NN I-MPA
Dysregulation NN O
of IN O
Wnt NNP O
inhibitory JJ O
factor NN O
1 CD O
( -LRB- O
Wif1 NNP O
) -RRB- O
expression NN O
resulted VBD O
in IN O
aberrant NN O
signaling NN O
and CC O
cell NN O
death NN O
of IN O
the DT O
cloaca NNS O
endoderm NN O
, , O
and CC O
anorectal JJ O
malformations NNS O
. . O

In IN O
mammalian JJ O
urorectal JJ O
development NN O
, , O
the DT O
urorectal JJ O
septum NN O
( -LRB- O
urs NNP O
) -RRB- O
descends VBZ O
from IN O
the DT O
ventral JJ O
body NN O
wall NN O
to IN O
the DT O
cloaca NNS O
membrane NN O
( -LRB- O
cm NN O
) -RRB- O
to TO O
partition VB O
the DT O
cloaca NNS O
into IN O
urogenital JJ O
sinus NN O
and CC O
rectum NN O
. . O

Defective JJ O
urs JJ O
growth NN O
results NNS O
in IN O
human JJ O
congenital JJ O
anorectal JJ O
malformations NNS O
( -LRB- O
ARMs NNPS O
) -RRB- O
, , O
and CC O
their PRP$ O
pathogenic JJ O
mechanisms NNS O
are VBP O
unclear JJ O
. . O

Recent JJ O
studies NNS O
only RB O
focused VBD O
on IN O
the DT O
importance NN O
of IN O
urs JJ O
mesenchyme NN O
proliferation NN O
, , O
which WDT O
is VBZ O
induced VBN O
by IN O
endoderm-derived NN O
Sonic NNP O
Hedgehog NNP O
( -LRB- O
Shh NNP O
) -RRB- O
. . O

Here RB O
, , O
we PRP O
showed VBD O
that IN O
the DT O
programmed VBN O
cell NN O
death NN O
of IN O
the DT O
apical JJ O
urs NNS O
and CC O
proximal JJ O
cm NN O
endoderm NN O
is VBZ O
particularly RB O
crucial JJ O
for IN O
the DT O
growth NN O
of IN O
urs NNS O
during IN O
septation NN O
. . O

The DT O
apoptotic JJ O
endoderm NN O
was VBD O
closely RB O
associated VBN O
with IN O
the DT O
tempo-spatial NN O
expression NN O
of IN O
Wnt NNP O
inhibitory JJ O
factor NN O
1 CD O
( -LRB- O
Wif1 NNP O
) -RRB- O
, , O
which WDT O
is VBZ O
an DT O
inhibitor NN O
of IN O
signaling NN O
. . O

In IN O
Wif1(lacZ NNP O
/ SYM O
lacZ JJ O
) -RRB- O
mutant JJ O
mice NNS O
and CC O
cultured VBD O
urorectum NN O
with IN O
exogenous JJ O
Wif1 NNP O
, , O
cloaca NNS O
septation NN O
was VBD O
defective JJ O
with IN O
undescended JJ O
urs NNS O
and CC O
hypospadias-like VB O
phenotypes NNS O
, , O
and CC O
such JJ O
septation NN O
defects NNS O
were VBD O
also RB O
observed VBN O
in IN O
Shh(-/- NNP O
) -RRB- O
mutants NNS O
and CC O
in IN O
endodermal JJ O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
mutants NNS O
. . O

In IN O
addition NN O
, , O
Wif1 NNP O
and CC O
Shh NNP O
were VBD O
expressed VBN O
in IN O
a DT O
complementary JJ O
manner NN O
in IN O
the DT O
cloaca NNS O
endoderm NN O
, , O
and CC O
Wif1 NNP O
was VBD O
ectopically RB O
expressed VBN O
in IN O
the DT O
urs NNS O
and CC O
cm NNS O
associated VBN O
with IN O
excessive JJ O
endodermal JJ O
apoptosis NN O
and CC O
septation NN O
defects NNS O
in IN O
Shh(-/- NNP O
) -RRB- O
mutants NNS O
. . O

Furthermore RB O
, , O
apoptotic JJ B-CPA
cells NNS I-CPA
were VBD O
markedly RB O
reduced VBN B-NegReg
in IN O
the DT O
endodermal JJ B-Protein
GOF NN B-PosReg
mutant JJ B-Var
Significance NN O
of IN O
the DT O
melanocortin NN O
1 CD O
receptor NN O
in IN O
the DT O
DNA NN O
damage NN O
response NN O
of IN O
human JJ O
melanocytes NNS O
to TO O
ultraviolet VB O
radiation NN O
. . O

Activation NNP O
of IN O
the DT O
melanocortin NN O
1 CD O
receptor NN O
( -LRB- O
MC1R NN O
) -RRB- O
by IN O
( -LRB- O
) -RRB- O
stimulates NNS O
eumelanin JJ O
synthesis NN O
and CC O
enhances VBZ O
repair NN O
of IN O
ultraviolet JJ O
radiation NN O
( -LRB- O
UV)-induced JJ O
DNA NN O
damage NN O
. . O

We PRP O
report VBP O
on IN O
the DT O
DNA NN O
damage NN O
response NN O
( -LRB- O
DDR NNP O
) -RRB- O
of IN O
human JJ O
melanocytes NNS O
to TO O
UV VB O
and CC O
its PRP$ O
enhancement NN O
by IN O
. . O

up-regulated RB O
the DT O
levels NNS O
of IN O
XPC NNP O
, , O
the DT O
enzyme NN O
that WDT O
recognizes VBZ O
DNA NN O
damage NN O
sites NNS O
, , O
enhanced VBD O
the DT O
UV-induced NN O
phosphorylation NN O
of IN O
the DT O
DNA NNP O
damage NN O
sensors NNS O
ataxia NN O
telangiectasia NN O
and CC O
Rad3-related VBN O
( -LRB- O
ATR NNP O
) -RRB- O
and CC O
ataxia NN O
telangiectasia NN O
mutated VBD O
( -LRB- O
ATM NNP O
) -RRB- O
and CC O
their PRP$ O
respect-ive NN O
substrates NNS O
checkpoint NN O
kinases VBZ O
1 CD O
and CC O
2 CD O
, , O
and CC O
increased VBD O
phosphorylated VBN O
H2AX NNP O
( -LRB- O
) -RRB- O
formation NN O
. . O

These DT O
effects NNS O
required VBD O
functional JJ O
MC1R NNP O
and CC O
were VBD O
absent JJ O
in IN O
melanocytes NNS O
expressing VBG O
loss NN O
of IN O
function NN O
( -LRB- O
LOF NNP O
) -RRB- O
MC1R. VB O
The DT O
levels NNS O
of IN O
wild-type JJ O
p53-induced JJ O
phosphatase NN O
1 CD O
( -LRB- O
Wip1 NNP O
) -RRB- O
, , O
which WDT O
dephosphorylates VBZ O
, , O
correlated VBD O
inversely RB O
with IN O
. . O

We PRP O
propose VBP O
that IN O
increases VBZ O
UV-induced NN O
to TO O
facilitate VB O
formation NN O
of IN O
DNA NNP O
repair NN O
complexes NNS O
and CC O
repair NN O
of IN O
DNA NN O
photoproducts NNS O
, , O
and CC O
LOF NNP B-Var
of IN O
MC1R NNP B-Protein
compromises VBZ B-NegReg
the DT O
DDR NNP B-MPA
and CC O
genomic JJ B-CPA
stability NN I-CPA
of IN I-CPA
melanocytes NNS I-CPA
Assessing VBG O
the DT O
functional JJ O
consequence NN O
of IN O
loss NN O
of IN O
function NN O
variants NNS O
using VBG O
electronic JJ O
medical JJ O
record NN O
and CC O
large-scale JJ O
genomics NNS O
consortium NN O
efforts NNS O
. . O

Estimates NNS O
from IN O
large JJ O
scale NN O
genome NN O
sequencing NN O
studies NNS O
indicate VBP O
that IN O
each DT O
human NN O
carries VBZ O
up RP O
to TO O
20 CD O
genetic JJ O
variants NNS O
that WDT O
are VBP O
predicted VBN O
to IN O
results NNS O
in IN O
loss NN O
of IN O
function NN O
( -LRB- O
LOF NNP O
) -RRB- O
of IN O
protein-coding NN O
genes NNS O
. . O

While IN O
some DT O
are VBP O
known VBN O
disease-causing NN O
variants NNS O
or CC O
common JJ O
, , O
tolerated VBN O
, , O
LOFs NNS O
in IN O
non-essential AFX O
genes NNS O
, , O
the DT O
majority NN O
remain VBP O
of IN O
unknown JJ O
consequence NN O
. . O

We PRP O
explore VBP O
the DT O
possibility NN O
of IN O
using VBG O
imputed VBN O
GWAS NNP O
data NNS O
from IN O
large JJ O
biorepositories NNS O
such JJ O
as IN O
the DT O
electronic JJ O
medical JJ O
record NN O
and CC O
genomics NNS O
( -LRB- O
eMERGE NNP O
) -RRB- O
consortium NN O
to TO O
determine VB O
the DT O
effects NNS O
of IN O
rare JJ O
LOFs NNS O
. . O

Here RB O
, , O
we PRP O
show VBP O
that IN O
two CD O
hypocholesterolemia-associated NN B-Disease
LOF NNP B-NegReg
mutations NNS B-Var
in IN O
the DT O
PCSK9 NNS B-Gene
PDGF NNP O
, , O
pericytes NNS O
and CC O
the DT O
pathogenesis NN O
of IN O
idiopathic JJ O
basal NN O
ganglia NNS O
calcification NN O
( -LRB- O
IBGC NN O
) -RRB- O
. . O

Platelet-derived NNP O
growth NN O
factors NNS O
( -LRB- O
PDGFs NNS O
) -RRB- O
are VBP O
important JJ O
mitogens NNS O
for IN O
various JJ O
types NNS O
of IN O
mesenchymal JJ O
cells NNS O
, , O
and CC O
as IN O
such JJ O
, , O
they PRP O
exert VBP O
critical JJ O
functions NNS O
during IN O
organogenesis NN O
in IN O
mammalian JJ O
embryonic JJ O
and CC O
early JJ O
postnatal JJ O
development NN O
. . O

Increased JJ O
or CC O
ectopic JJ B-Var
PDGF NNP B-Protein
activity NN B-MPA
may MD O
also RB O
cause VB B-Reg
or CC O
contribute VB B-Reg
to IN O
diseases NNS O
such JJ O
as IN O
cancer NN B-Disease
and CC O
tissue NN B-Disease
fibrosis NN I-Disease
. . O

Until IN O
recently RB O
, , O
no DT O
loss-of-function NN O
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS O
in IN O
PDGF NNP O
or CC O
PDGF NNP O
receptor NN O
genes NNS O
were VBD O
reported VBN O
as IN O
causally RB O
linked VBN O
to IN O
a DT O
human JJ O
disease NN O
. . O

This DT O
changed VBD O
in IN O
2013 CD O
when WRB O
reports NNS O
appeared VBD O
on IN O
presumed VBN O
LOF IN B-NegReg
mutations NNS B-Var
in IN O
the DT O
genes NNS O
encoding VBG O
PDGF-B NNP B-Gene
and CC O
its PRP$ O
receptor NN O
PDGF JJ O
receptor-beta NN O
( -LRB- O
) -RRB- O
in IN O
familial JJ B-Disease
idiopathic JJ I-Disease
basal NN I-Disease
ganglia NNS I-Disease
calcification NN I-Disease
Mutant JJ O
p53 VBP O
gains NNS O
new JJ O
function NN O
in IN O
promoting VBG O
inflammatory JJ O
signals NNS O
by IN O
repression NN O
of IN O
the DT O
secreted JJ O
interleukin-1 DT O
receptor NN O
antagonist NN O
. . O

The DT O
TP53 NNP B-Gene
tumor-suppressor NN I-Gene
gene NN I-Gene
is VBZ O
frequently RB O
mutated VBN O
in IN O
human JJ O
cancer NN O
. . O

Missense NN B-Var
mutations NNS I-Var
can MD O
add VB O
novel JJ O
functions NNS O
( -LRB- O
gain-of-function NN O
, , O
GOF NNP O
) -RRB- O
that WDT O
promote VBP B-PosReg
tumor NN B-CPA
malignancy NN I-CPA
. . O

Here RB O
we PRP O
report VBP O
that IN O
mutant JJ B-Var
( -LRB- O
mut NN O
) -RRB- O
p53 NN B-Gene
promotes VBZ B-PosReg
tumor NN B-CPA
malignancy NN I-CPA
by IN O
suppressing VBG B-NegReg
the DT O
expression NN B-MPA
of IN I-MPA
a DT I-MPA
natural JJ I-MPA
occurring VBG I-MPA
anti-inflammatory RB I-MPA
cytokine NN I-MPA
, , O
the DT O
secreted JJ O
interleukin-1 DT O
receptor NN O
antagonist NN O
( -LRB- O
sIL-1Ra NNS O
, , O
IL1RN NNP O
) -RRB- O
. . O

We PRP O
show VBP O
that IN O
mutp53 NN B-Var
but CC O
not RB O
wild-type JJ O
( -LRB- O
wt NNP O
) -RRB- O
p53 NN O
suppresses NNS B-NegReg
the DT O
sIL-1Ra NNS B-MPA
production NN I-MPA
Rare JJ O
variants NNS O
in IN O
PPARG NNP O
with IN O
decreased JJ O
activity NN O
in IN O
adipocyte NN O
differentiation NN O
are VBP O
associated VBN O
with IN O
increased VBN O
risk NN O
of IN O
type NN O
2 CD O
diabetes NNS O
. . O

Peroxisome JJ O
proliferator-activated NN O
receptor NN O
gamma NN O
( -LRB- O
PPARG NNP O
) -RRB- O
is VBZ O
a DT O
master NN O
transcriptional JJ O
regulator NN O
of IN O
adipocyte NN O
differentiation NN O
and CC O
a DT O
canonical JJ O
target NN O
of IN O
antidiabetic JJ O
thiazolidinedione NN O
medications NNS O
. . O

In IN O
rare JJ O
families NNS O
, , O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS B-Var
in IN O
PPARG NNP B-Gene
are VBP O
known VBN O
to TO O
cosegregate VB O
with IN O
lipodystrophy NN B-Disease
and CC O
insulin NN B-Disease
resistance NN I-Disease
; : O
in IN O
the DT O
general JJ O
population NN O
, , O
the DT O
common JJ O
P12A NN B-Var
variant NN I-Var
is VBZ O
associated VBN O
with IN O
a DT O
decreased JJ B-NegReg
risk NN O
of IN O
type NN B-Disease
2 CD I-Disease
diabetes NNS I-Disease
( -LRB- O
T2D NNP O
) -RRB- O
. . O

Whether IN O
and CC O
how WRB O
rare JJ O
variants NNS O
in IN O
PPARG NNP O
and CC O
defects NNS O
in IN O
adipocyte NN O
differentiation NN O
influence NN O
risk NN O
of IN O
T2D NN O
in IN O
the DT O
general JJ O
population NN O
remains VBZ O
undetermined JJ O
. . O

By IN O
sequencing VBG O
PPARG NNP O
in IN O
19,752 CD O
T2D NN O
cases NNS O
and CC O
controls NNS O
drawn VBN O
from IN O
multiple JJ O
studies NNS O
and CC O
ethnic JJ O
groups NNS O
, , O
we PRP O
identified VBD O
49 CD O
previously RB O
unidentified JJ O
, , O
nonsynonymous JJ O
PPARG NNP O
variants NNS O
( -LRB- O
MAF NNP O
< XX O
0.5 CD O
% NN O
) -RRB- O
. . O

Considered VBN O
in IN O
aggregate NN O
( -LRB- O
with IN O
or CC O
without IN O
computational JJ O
prediction NN O
of IN O
functional JJ O
consequence NN O
) -RRB- O
, , O
these DT O
rare JJ O
variants NNS O
showed VBD O
no DT O
association NN O
with IN O
T2D NNP O
( -LRB- O
OR CC O
= SYM O
1.35 CD O
; : O
P NN O
= SYM O
0.17 CD O
) -RRB- O
. . O

The DT O
function NN O
of IN O
the DT O
49 CD O
variants NNS O
was VBD O
experimentally RB O
tested VBN O
in IN O
a DT O
novel JJ O
high-throughput JJ O
human JJ O
adipocyte NN O
differentiation NN O
assay JJ O
, , O
and CC O
nine CD O
were VBD O
found VBN O
to TO O
have VB O
reduced VBN O
activity NN O
in IN O
the DT O
assay NN O
. . O

Carrying VBG O
any DT O
of IN O
these DT O
nine CD O
LOF NNP O
variants NNS O
was VBD O
associated VBN O
with IN O
a DT O
substantial JJ O
increase NN O
in IN O
risk NN O
of IN O
T2D NNP O
( -LRB- O
OR CC O
= SYM O
7.22 CD O
; : O
P NN O
= SYM O
0.005 CD O
) -RRB- O
. . O

The DT O
combination NN O
of IN O
large-scale JJ O
DNA NN O
sequencing NN O
and CC O
functional JJ O
testing NN O
in IN O
the DT O
laboratory NN O
reveals VBZ O
that IN O
approximately RB O
1 CD O
in IN O
1,000 CD O
individuals NNS O
carries VBZ O
a DT O
variant NN B-Var
in IN O
PPARG NNP B-Gene
that IN O
reduces VBZ B-NegReg
function VBP B-CPA
in IN I-CPA
a DT I-CPA
human JJ I-CPA
adipocyte NN I-CPA
differentiation NN I-CPA
assay JJ I-CPA
and CC O
is VBZ O
associated VBN B-Reg
with IN O
a DT O
substantial JJ O
risk NN O
of IN O
T2D. NN B-Disease
Loss-of-function NN O
de IN O
novo NN O
mutations NNS O
play VBP O
an DT O
important JJ O
role NN O
in IN O
severe JJ O
human JJ O
neural JJ O
tube NN O
defects NNS O
. . O

BACKGROUND NNP O
: : O
Neural JJ O
tube NN O
defects NNS O
( -LRB- O
NTDs NNS O
) -RRB- O
are VBP O
very RB O
common JJ O
and CC O
severe JJ O
birth NN O
defects NNS O
that WDT O
are VBP O
caused VBN O
by IN O
failure NN O
of IN O
neural JJ O
tube NN O
closure NN O
and CC O
that WDT O
have VBP O
a DT O
complex JJ O
aetiology NN O
. . O

Anencephaly NNS O
and CC O
spina NN O
bifida NN O
are VBP O
severe JJ O
NTDs NNS O
that WDT O
affect VBP O
reproductive JJ O
fitness NN O
and CC O
suggest VB O
a DT O
role NN O
for IN O
de FW O
novo NN O
mutations NNS O
( -LRB- O
DNMs NNS O
) -RRB- O
in IN O
their PRP$ O
aetiology NN O
. . O

METHODS NNS O
: : O
We PRP O
used VBD O
whole-exome JJ O
sequencing NN O
in IN O
43 CD O
sporadic JJ O
cases NNS O
affected VBN O
with IN O
myelomeningocele NN O
or CC O
anencephaly NNS O
and CC O
their PRP$ O
unaffected JJ O
parents NNS O
to TO O
identify VB O
DNMs NNS O
in IN O
their PRP$ O
exomes NNS O
. . O

RESULTS NNS O
: : O
We PRP O
identified VBD O
42 CD O
coding VBG O
DNMs NNS O
in IN O
25 CD O
cases NNS O
, , O
of IN O
which WDT O
6 CD O
were VBD O
loss NN O
of IN O
function NN O
( -LRB- O
LoF NN O
) -RRB- O
showing VBG O
a DT O
higher JJR O
rate NN O
of IN O
LoF NNP O
DNM NNP O
in IN O
our PRP$ O
cohort NN O
compared VBN O
with IN O
control NN O
cohorts NNS O
. . O

Notably RB O
, , O
we PRP O
identified VBD O
two CD O
protein-truncating NN B-Protein
DNMs NNS O
in IN O
two CD O
independent JJ O
cases NNS O
in IN O
SHROOM3 NNP O
, , O
previously RB O
associated VBN O
with IN O
NTDs NNS O
only RB O
in IN O
animal NN O
models NNS O
. . O

We PRP O
have VBP O
demonstrated VBN O
a DT O
significant JJ O
enrichment NN O
of IN O
LoF NN O
DNMs NNS O
in IN O
this DT O
gene NN O
in IN O
NTDs NNS O
compared VBN O
with IN O
the DT O
gene NN O
specific JJ O
DNM NNP O
rate NN O
and CC O
to IN O
the DT O
DNM NNP O
rate NN O
estimated VBN O
from IN O
control NN O
cohorts NNS O
. . O

We PRP O
also RB O
identified VBD O
one CD O
nonsense NN O
DNM NNP O
in IN O
PAX3 NNP O
and CC O
two CD O
potentially RB O
causative JJ O
missense NN O
DNMs NNS O
in IN O
GRHL3 NN O
and CC O
PTPRS JJ O
. . O

CONCLUSIONS NNS O
: : O
Our PRP$ O
study NN O
demonstrates VBZ O
an DT O
important JJ O
role NN O
of IN O
LoF NN O
DNMs NNS O
in IN O
the DT O
development NN O
of IN O
NTDs NNS O
and CC O
strongly RB O
implicates NNS O
SHROOM3 VBP O
in IN O
its PRP$ O
aetiology NN O
. . O

Analysis NN O
of IN O
loss-of-function NN O
variants NNS O
and CC O
20 CD O
risk NN O
factor NN O
phenotypes NNS O
in IN O
8,554 CD O
individuals NNS O
identifies NNS O
loci NNS O
influencing VBG O
chronic JJ O
disease NN O
. . O

A DT O
typical JJ O
human JJ O
exome NN O
harbors NNS O
dozens NNS O
of IN O
loss-of-function NN O
( -LRB- O
LOF NNP O
) -RRB- O
variants NNS O
, , O
which WDT O
can MD O
lower VB O
disease NN O
risk NN O
factor NN O
levels NNS O
and CC O
affect VB O
drug NN O
efficacy NN O
. . O

We PRP O
hypothesized VBD O
that IN O
LOF NNP O
variants NNS O
are VBP O
enriched VBN O
in IN O
genes NNS O
influencing VBG O
risk NN O
factor NN O
levels NNS O
and CC O
the DT O
onset NN O
of IN O
common JJ O
chronic JJ O
diseases NNS O
, , O
such JJ O
as IN O
cardiovascular JJ O
disease NN O
and CC O
diabetes NN O
. . O

To TO O
test VB O
this DT O
hypothesis NN O
, , O
we PRP O
sequenced VBD O
the DT O
exomes NNS O
of IN O
8,554 CD O
individuals NNS O
and CC O
analyzed VBD O
the DT O
effects NNS O
of IN O
predicted VBN O
LOF NNP O
variants NNS O
on IN O
20 CD O
chronic JJ O
disease NN O
risk NN O
factor NN O
phenotypes NNS O
. . O

Analysis NN O
of IN O
this DT O
sample NN O
as IN O
discovery NN O
and CC O
replication NN O
strata NNS O
of IN O
equal JJ O
size NN O
verified VBD O
two CD O
relationships NNS O
in IN O
well-studied RB O
genes NNS O
( -LRB- O
PCSK9 NNS O
and CC O
APOC3 NNP O
) -RRB- O
and CC O
identified VBD O
eight CD O
new JJ O
loci NN O
. . O

Previously RB O
unknown JJ O
relationships NNS O
included VBD O
elevated JJ B-PosReg
fasting VBG O
glucose NN B-MPA
in IN O
carriers NNS O
of IN O
heterozygous JJ O
LOF NNP B-NegReg
variation NN B-Var
in IN O
TXNDC5 NN B-Gene
, , O
which WDT O
encodes VBZ O
a DT O
biomarker NN O
for IN O
type NN O
1 CD O
diabetes NN O
progression NN O
, , O
and CC O
apparent JJ O
recessive JJ B-NegReg
effects NNS I-NegReg
of IN O
C1QTNF8 NN B-Gene
on IN O
serum NN B-MPA
magnesium NN I-MPA
levels NNS I-MPA
Mutant JJ O
p53-Heat NN O
Shock NNP O
Response NNP O
Oncogenic NNP O
Cooperation NN O
: : O
A DT O
New NNP O
Mechanism NNP O
of IN O
Cancer NNP O
Cell NNP O
Survival NNP O
. . O

The DT O
main JJ O
tumor NN O
suppressor NN O
function NN O
of IN O
p53 NN O
as IN O
a DT O
" `` O
guardian NN O
of IN O
the DT O
genome NN O
" `` O
is VBZ O
to TO O
respond VB O
to IN O
cellular JJ O
stress NN O
by IN O
transcriptional JJ O
activation NN O
of IN O
apoptosis NN O
, , O
growth NN O
arrest NN O
, , O
or CC O
senescence NN O
in IN O
damaged JJ O
cells NNS O
. . O

Not RB O
surprisingly RB O
, , O
mutations NNS O
in IN O
the DT O
p53 NN O
gene NN O
are VBP O
the DT O
most RBS O
frequent JJ O
genetic JJ O
alteration NN O
in IN O
human JJ O
cancers NNS O
. . O

Importantly RB O
, , O
mutant JJ B-Var
p53 NN B-Gene
( -LRB- O
mutp53 NN O
) -RRB- O
proteins NNS B-Protein
not RB O
only RB O
lose VBP B-NegReg
their PRP$ O
wild-type JJ O
tumor NN B-CPA
suppressor NN I-CPA
activity NN I-CPA
but CC O
also RB O
can MD O
actively RB B-PosReg
promote VB I-PosReg
tumor NN B-CPA
development NN I-CPA
. . O

Two CD O
main JJ O
mechanisms NNS O
accounting VBG O
for IN O
mutp53 NN B-Var
proto-oncogenic NN O
activity NN O
are VBP O
inhibition NN O
of IN O
the DT O
wild-type JJ O
p53 NN O
in IN O
a DT O
dominant-negative JJ O
fashion NN O
and CC O
gain NN B-PosReg
of IN O
additional JJ B-CPA
oncogenic JJ I-CPA
activities NNS I-CPA
known VBN O
as IN O
gain-of-function NN O
( -LRB- O
GOF NN O
) -RRB- O
. . O

Here RB O
, , O
we PRP O
discuss VBP O
a DT O
novel JJ O
mechanism NN O
of IN O
mutp53 NN B-Var
GOF NN O
, , O
which WDT O
relies VBZ O
on IN O
its PRP$ O
oncogenic JJ O
cooperation NN O
with IN O
the DT O
heat NN O
shock NN O
machinery NN O
. . O

This DT O
coordinated VBD O
adaptive JJ O
mechanism NN O
renders VBZ O
cancer NN O
cells NNS O
more RBR B-PosReg
resistant JJ B-CPA
to IN I-CPA
proteotoxic JJ I-CPA
stress NN I-CPA
and CC O
provides VBZ O
both DT O
, , O
a DT O
strong JJ O
survival NN B-CPA
advantage NN I-CPA
Identification NN O
and CC O
functional JJ O
characterization NN O
of IN O
natural JJ O
human JJ O
melanocortin NN O
1 CD O
receptor NN O
mutant JJ O
alleles NNS O
in IN O
Pakistani JJ O
population NN O
. . O

Melanocortin NNP O
1 CD O
receptor NN O
( -LRB- O
MC1R NN O
) -RRB- O
, , O
a DT O
Gs NNP O
protein-coupled NN O
receptor NN O
of IN O
the DT O
melanocyte NN O
's POS O
plasma NN O
membrane NN O
, , O
is VBZ O
a DT O
major JJ O
determinant NN O
of IN O
skin NN O
pigmentation NN O
and CC O
phototype NN O
. . O

Upon IN O
activation NN O
by IN O
stimulating VBG O
hormone NN O
, , O
MC1R NNP O
triggers VBZ O
the DT O
cAMP NN O
cascade NN O
to TO O
stimulate VB O
eumelanogenesis NN O
. . O

We PRP O
used VBD O
whole-exome JJ O
sequencing NN O
to TO O
identify VB O
causative JJ O
alleles NNS O
in IN O
Pakistani JJ O
families NNS O
with IN O
skin NN O
and CC O
hair NN O
hypopigmentation NN O
. . O

Six CD O
MC1R NN O
mutations NNS O
segregated VBD O
with IN O
the DT O
phenotype NN O
in IN O
seven CD O
families NNS O
, , O
including VBG O
a DT O
p NN O
. . O

Val174del IN O
in-frame IN O
deletion NN O
and CC O
a DT O
p NN O
. . O

Tyr298 JJ O
* NFP O
nonsense NN O
mutation NN O
, , O
that WDT O
were VBD O
analyzed VBN O
for IN O
function NN O
in IN O
heterologous JJ O
HEK293 NNP O
cells NNS O
. . O

p LS B-Var
. . O

Tyr298 JJ O
* NFP O
MC1R NN B-Gene
showed VBD O
no DT B-NegReg
agonist-induced NN B-MPA
signaling NN I-MPA
to IN O
the DT O
cAMP NN B-Pathway
or CC O
ERK NNP B-Pathway
pathways NNS I-Pathway
, , O
nor CC B-NegReg
detectable JJ O
agonist JJ B-Interaction
binding JJ I-Interaction
. . O

Conversely RB O
, , O
signaling NN O
was VBD O
comparable JJ O
for IN O
p NN B-Var
. . O

Val174del NN O
and CC O
wild-type JJ O
in IN O
HEK NNP O
cells NNS O
overexpressing VBG O
the DT O
proteins NNS O
, , O
but CC O
binding VBG O
analysis NN O
suggested VBD O
impaired JJ B-NegReg
cell NN B-MPA
surface NN I-MPA
expression NN I-MPA
. . O

Flow JJ O
cytometry NN O
and CC O
confocal JJ O
imaging JJ O
studies NNS O
revealed VBD O
reduced JJ B-NegReg
plasma NN B-MPA
membrane JJ I-MPA
expression NN I-MPA
of IN O
p NN B-Var
. . O

Val174del NN O
and CC O
p NN B-Var
. . O

Tyr298*. NN O
Therefore RB O
, , O
p UH B-Var
. . O

Tyr298 JJ O
* NFP O
was VBD O
a DT O
total JJ O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
allele NN O
, , O
while IN O
p XX B-Var
. . O

Val174del NNP O
displayed VBD O
a DT O
partial JJ B-NegReg
LOF NNP I-NegReg
Gain-of-function NN O
p53 NN O
mutants NNS O
co-opt VBP O
chromatin NN O
pathways NNS O
to TO O
drive VB O
cancer NN O
growth NN O
. . O

TP53 NNP O
( -LRB- O
which WDT O
encodes NNS O
p53 NN O
protein NN O
) -RRB- O
is VBZ O
the DT O
most RBS O
frequently RB O
mutated VBN O
gene NN O
among IN O
all DT O
human JJ O
cancers NNS O
. . O

Prevalent JJ O
p53 NN B-Gene
missense NN B-Var
mutations NNS I-Var
abrogate VBP B-NegReg
its PRP$ O
tumour NN B-CPA
suppressive JJ I-CPA
function NN I-CPA
and CC O
lead NN O
to IN O
a DT O
' `` O
gain-of-function JJ B-PosReg
' '' O
( -LRB- O
GOF NN O
) -RRB- O
that WDT O
promotes VBZ B-PosReg
cancer NN B-Disease
. . O

Here RB O
we PRP O
show VBP O
that IN O
p53 VBP B-Gene
GOF NN B-PosReg
mutants NNS B-Var
bind VBP O
to IN O
and CC O
upregulate JJ B-PosReg
chromatin JJ B-Gene
regulatory JJ I-Gene
genes NNS I-Gene
, , O
including VBG O
the DT O
methyltransferases NNS B-Enzyme
MLL1 NNP I-Enzyme
( -LRB- O
also RB O
known VBN O
as IN O
KMT2A NNP O
) -RRB- O
, , O
MLL2 NNP B-Enzyme
( -LRB- O
also RB O
known VBN O
as IN O
KMT2D NNP O
) -RRB- O
, , O
and CC O
acetyltransferase NN B-Enzyme
MOZ NNP I-Enzyme
( -LRB- O
also RB O
known VBN O
as IN O
KAT6A JJ O
or CC O
MYST3 NNP O
) -RRB- O
, , O
resulting VBG O
in IN O
genome-wide NN O
increases NNS B-PosReg
of IN O
histone NN B-MPA
methylation NN I-MPA
and CC O
acetylation NN B-MPA
. . O

Analysis NN O
of IN O
The DT O
Cancer NNP O
Genome NNP O
Atlas NNP O
shows VBZ O
specific JJ O
upregulation NN B-PosReg
of IN O
MLL1 NNP B-Enzyme
, , O
MLL2 NNP B-Enzyme
, , O
and CC O
MOZ NNP B-Enzyme
in IN O
p53 CD B-Gene
GOF NNP B-Var
DNA NN O
damage-induced NN O
ephrin-B2 NN O
reverse JJ O
signaling NN O
promotes NNS O
chemoresistance NN O
and CC O
drives VBZ O
EMT NNP O
in IN O
colorectal NN O
carcinoma NN O
harboring VBG O
mutant JJ O
p53 NN O
. . O

Mutation NNP O
in IN O
the DT O
TP53 NNP O
gene NN O
positively RB O
correlates VBZ O
with IN O
increased VBN O
incidence NN O
of IN O
chemoresistance NN O
in IN O
different JJ O
cancers NNS O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
investigated VBD O
the DT O
mechanism NN O
of IN O
chemoresistance NN O
and CC O
epithelial-to-mesenchymal NN O
transition NN O
( -LRB- O
EMT NNP O
) -RRB- O
in IN O
colorectal NN O
cancer NN O
involving VBG O
the DT O
gain-of-function JJ O
( -LRB- O
GOF NN O
) -RRB- O
mutant JJ O
p53/ephrin-B2 NNP O
signaling NN O
axis NN O
. . O

Bioinformatic JJ O
analysis NN O
of IN O
the DT O
NCI-60 NNP O
data NNS O
set VBN O
and CC O
subsequent JJ O
hub NN O
prediction NN O
identified VBN O
EFNB2 VBZ O
as IN O
a DT O
possible JJ O
GOF NN O
mutant JJ O
p53 NN O
target NN O
gene NN O
, , O
responsible JJ O
for IN O
chemoresistance NN O
. . O

We PRP O
show VBP O
that IN O
the DT O
mutant JJ B-Var
p53-NF-Y NNP B-Gene
complex NN O
transcriptionally RB O
upregulates VBZ B-PosReg
EFNB2 IN B-Gene
expression NN B-MPA
in IN O
response NN B-MPA
to IN I-MPA
DNA NN I-MPA
damage NN I-MPA
. . O

Moreover RB O
, , O
the DT O
acetylated VBN O
form NN O
of IN O
mutant JJ B-Var
p53 NN B-Gene
protein NN B-Protein
is VBZ O
recruited VBN B-PosReg
on IN O
the DT O
EFNB2 NNP O
promoter NN O
and CC O
positively RB O
regulates VBZ B-Reg
its PRP$ O
expression NN B-MPA
in IN O
conjunction NN O
with IN O
coactivator NN O
p300 NN O
. . O

In IN O
vitro FW O
cell NN O
line NN O
and CC O
in IN O
vivo NN O
nude JJ O
mice NNS O
data NNS O
show VBP O
that WDT O
EFNB2 VBZ O
silencing VBG O
restores VBZ O
chemosensitivity NN O
in IN O
mutant JJ O
p53-harboring VBG O
tumors NNS O
. . O

In IN O
addition NN O
, , O
we PRP O
observed VBD O
high JJ O
expression NN O
of IN O
EFNB2 NNP O
in IN O
patients NNS O
having VBG O
neoadjuvant JJ O
non-responder AFX O
colorectal NN O
carcinoma NN O
compared VBN O
with IN O
those DT O
having VBG O
responder NN O
version NN O
of IN O
the DT O
disease NN O
. . O

In IN O
the DT O
course NN O
of IN O
deciphering VBG O
the DT O
drug NN O
resistance NN O
mechanism NN O
, , O
we PRP O
also RB O
show VBP O
that IN O
ephrin-B2 NN O
reverse JJ O
signaling NN O
induces NNS B-PosReg
ABCG2 NN B-Gene
expression NN B-MPA
after IN O
drug NN O
treatment NN O
that WDT O
involves VBZ O
JNK-c-Jun NNP B-MPA
signaling VBG I-MPA
in IN O
mutant JJ B-Var
p53 NN B-Gene
Urine-sample-derived NN O
human JJ O
induced VBN O
pluripotent NN O
stem NN O
cells NNS O
as IN O
a DT O
model NN O
to TO O
study VB O
PCSK9-mediated VBN O
autosomal NN O
dominant JJ O
hypercholesterolemia NN O
. . O

Proprotein NNP O
convertase NN O
subtilisin JJ O
kexin NN O
type NN O
9 CD O
( -LRB- O
PCSK9 NNS O
) -RRB- O
is VBZ O
a DT O
critical JJ O
modulator NN O
of IN O
cholesterol NN O
homeostasis NN O
. . O

Whereas IN O
PCSK9 NNS B-Gene
gain-of-function VBP B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
are VBP O
associated VBN O
with IN O
autosomal NN B-Disease
dominant JJ I-Disease
hypercholesterolemia NN I-Disease
( -LRB- O
ADH NNP O
) -RRB- O
and CC O
premature JJ B-Disease
atherosclerosis NN I-Disease
, , O
PCSK9 NNS B-Gene
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS B-Var
have VBP B-PosReg
a DT O
cardio-protective NN B-CPA
effect NN I-CPA
and CC O
in IN O
some DT O
cases NNS O
can MD O
lead VB O
to IN O
familial JJ B-Disease
hypobetalipoproteinemia NN I-Disease
Recurrent NNP O
MLK4 NNP B-Gene
Loss-of-Function NNP B-NegReg
Mutations NNP B-Var
Suppress NNP B-NegReg
JNK NNP B-Pathway
Signaling NNP I-Pathway
to IN O
Promote NNP B-PosReg
Colon NNP B-Disease
Tumorigenesis NNP I-Disease
. . O

MLK4 NNP O
is VBZ O
a DT O
member NN O
of IN O
the DT O
mixed-lineage JJ O
family NN O
of IN O
kinases NNS O
that WDT O
regulate VBP O
the DT O
JNK NNP O
, , O
p38 CD O
, , O
and CC O
ERK NNP O
kinase VBP O
signaling VBG O
pathways NNS O
. . O

MLK4 NNP O
mutations NNS O
have VBP O
been VBN O
identified VBN O
in IN O
various JJ O
human JJ O
cancers NNS O
, , O
including VBG O
frequently RB O
in IN O
colorectal NN O
cancer NN O
, , O
where WRB O
their PRP$ O
function NN O
and CC O
pathobiological JJ O
importance NN O
have VBP O
been VBN O
uncertain JJ O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
assessed VBD O
the DT O
functional JJ O
consequences NNS O
of IN O
MLK4 NNP O
mutations NNS O
in IN O
colon NN O
tumorigenesis NN O
. . O

Biochemical NNP O
data NNS O
indicated VBD O
that IN O
a DT O
majority NN O
of IN O
MLK4 NNP B-Gene
mutations NNS B-Var
are VBP O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
mutations NNS O
that WDT O
can MD O
exert VB O
dominant-negative JJ O
effects NNS O
. . O

In IN O
seeking VBG O
to TO O
understand VB O
the DT O
abrogated JJ O
activity NN O
of IN O
these DT O
mutants NNS O
, , O
we PRP O
elucidated VBD O
a DT O
new JJ O
MLK4 NNP O
catalytic JJ O
domain NN O
structure NN O
. . O

To TO O
determine VB O
whether IN O
MLK4 NNP O
is VBZ O
required VBN O
to TO O
maintain VB O
tumorigenic JJ O
phenotypes NNS O
, , O
we PRP O
reconstituted VBD O
its PRP$ O
signaling NN O
axis NN O
in IN O
colon NN O
cancer NN O
cells NNS O
harboring VBG O
MLK4-inactivating NN O
mutations NNS O
. . O

We PRP O
found VBD O
that IN O
restoring VBG O
MLK4 NNP O
activity NN O
reduced VBD O
cell NN O
viability NN O
, , O
proliferation NN O
, , O
and CC O
colony NN O
formation NN O
in IN O
vitro FW O
and CC O
delayed VBN O
tumor NN O
growth NN O
in IN O
vivo NN O
. . O

Mechanistic JJ O
investigations NNS O
established VBN O
that IN O
restoring VBG O
the DT O
function NN O
of IN O
MLK4 NNP O
selectively RB O
induced VBD O
the DT O
JNK NNP O
pathway NN O
and CC O
its PRP$ O
downstream JJ O
targets NNS O
, , O
cJUN NNS O
, , O
ATF3 NNP O
, , O
and CC O
the DT O
cyclin-dependent NN O
kinase NN O
inhibitors NNS O
CDKN1A VBP O
and CC O
CDKN2B. NNP O
Our PRP$ O
work NN O
indicates VBZ O
that IN O
MLK4 NNP B-Gene
is VBZ O
a DT O
novel JJ O
tumor-suppressing NN O
kinase NN O
harboring VBG O
frequent JJ O
LOF NNP B-NegReg
mutations NNS B-Var
that WDT O
lead VBP O
to IN O
diminished VBN B-NegReg
signaling VBG B-MPA
in IN O
the DT O
JNK NNP B-Pathway
pathway NN I-Pathway
and CC O
enhanced VBD B-PosReg
proliferation NN B-CPA
Transcriptome VB O
profiling NN O
identifies NNS O
genes NNS O
and CC O
pathways NNS O
deregulated VBN O
upon IN O
floxuridine JJ O
treatment NN O
in IN O
colorectal NN O
cancer NN O
cells NNS O
harboring VBG O
GOF NN O
mutant JJ O
p53 NN O
. . O

Mutation NNP O
in IN O
TP53 NNP O
is VBZ O
a DT O
common JJ O
genetic JJ O
alteration NN O
in IN O
human JJ O
cancers NNS O
. . O

Certain JJ O
tumor NN O
associated VBD O
p53 NN B-Gene
missense NN B-Var
mutants NNS I-Var
acquire VBP O
gain-of-function NN B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
properties NNS O
and CC O
confer VB O
oncogenic JJ O
phenotypes NNS O
including VBG O
enhanced VBN B-PosReg
chemoresistance NN B-CPA
. . O

The DT O
colorectal NN O
cancers NNS O
( -LRB- O
CRC NNP O
) -RRB- O
harboring VBG O
mutant JJ O
p53 NN O
are VBP O
generally RB O
aggressive JJ O
in IN O
nature NN O
and CC O
difficult JJ O
to TO O
treat VB O
. . O

To TO O
identify VB O
a DT O
potential JJ O
gene NN O
expression NN O
signature NN O
of IN O
GOF NN O
mutant JJ O
p53-driven JJ O
acquired VBN O
chemoresistance NN O
in IN O
CRC NNP O
, , O
we PRP O
performed VBD O
transcriptome VBP O
profiling NN O
of IN O
floxuridine NN O
( -LRB- O
FUdR NNP O
) -RRB- O
treated VBD O
SW480 NN O
cells NNS O
expressing VBG O
mutant JJ O
p53(R273H NN O
) -RRB- O
( -LRB- O
GEO NNP O
# $ O
: : O
GSE77533 NNP O
) -RRB- O
. . O

We PRP O
obtained VBD O
several JJ O
genes NNS O
differentially RB O
regulated VBN O
between IN O
FUdR NNP O
treated VBN O
and CC O
untreated JJ O
cells NNS O
. . O

Further RB O
, , O
functional JJ O
characterization NN O
and CC O
pathway NN O
analysis NN O
revealed VBD O
significant JJ O
enrichment NN O
of IN O
crucial JJ O
biological JJ O
processes NNS O
and CC O
pathways NNS O
upon IN O
FUdR NNP O
treatment NN O
in IN O
SW480 NNP O
cells NNS O
. . O

Our PRP$ O
data NNS O
suggest VBP O
that IN O
in IN O
response NN O
to IN O
chemotherapeutics NNS O
treatment NN O
, , O
cancer NN O
cells NNS O
with IN O
GOF NN B-PosReg
mutant JJ B-Var
p53 NN B-Gene
can MD O
modulate VB B-Reg
key JJ B-Pathway
cellular JJ I-Pathway
pathways NNS I-Pathway
to TO O
withstand VB B-CPA
the DT I-CPA
cytotoxic JJ I-CPA
effect NN I-CPA
of IN I-CPA
the DT I-CPA
drugs NNS I-CPA
TBR1 NNS O
regulates VBZ O
autism NN O
risk NN O
genes NNS O
in IN O
the DT O
developing VBG O
neocortex NN O
. . O

Exome NNP O
sequencing NN O
studies NNS O
have VBP O
identified VBN O
multiple JJ O
genes NNS O
harboring VBG O
de IN O
novo NN O
loss-of-function NN B-NegReg
( -LRB- O
LoF NN O
) -RRB- O
variants NNS B-Var
in IN O
individuals NNS O
with IN O
autism NN B-Disease
spectrum NN I-Disease
disorders NNS I-Disease
( -LRB- O
ASD NN O
) -RRB- O
, , O
including VBG O
TBR1 NNP B-Gene
A DT O
rare JJ O
DNA NN O
contact NN O
mutation NN B-Var
in IN O
cancer NN O
confers NNS B-PosReg
p53 VBP B-Gene
gain-of-function JJ B-PosReg
and CC O
tumor NN B-CPA
cell NN I-CPA
survival NN I-CPA
via IN O
TNFAIP8 NNP B-Gene
induction NN O
. . O

The DT O
p53 NN O
tumor NN O
suppressor NN O
gene NN O
encodes NNS O
a DT O
sequence-specific NN O
transcription NN O
factor NN O
. . O

Mutations NNS B-Var
in IN O
the DT O
coding NN O
sequence NN O
of IN O
p53 NN B-Gene
occur NN O
frequently RB O
in IN O
human JJ O
cancer NN O
and CC O
often RB O
result VBP B-Reg
in IN I-Reg
single JJ B-Var
amino NN I-Var
acid NN I-Var
substitutions NNS I-Var
( -LRB- I-Var
missense NN I-Var
mutations NNS I-Var
) -RRB- I-Var
in IN I-Var
the DT I-Var
DNA NN I-Var
binding VBG O
domain NN O
( -LRB- O
DBD NNP O
) -RRB- O
, , O
blocking VBG B-NegReg
normal JJ O
tumor NN B-CPA
suppressive JJ I-CPA
functions NNS I-CPA
. . O

In IN O
addition NN O
to IN O
the DT O
loss NN O
of IN O
canonical JJ O
functions NNS O
, , O
some DT O
missense NN B-Var
mutations NNS I-Var
in IN O
p53 NN B-Gene
confer JJ O
gain-of-function JJ B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
activities NNS B-CPA
to IN I-CPA
tumor NN I-CPA
cells NNS I-CPA
. . O

While IN O
many JJ O
missense NN O
mutations NNS O
in IN O
p53 NN O
cluster NN O
at IN O
six CD O
" `` O
hotspot JJ O
" '' O
amino JJ O
acids NNS O
, , O
the DT O
majority NN O
of IN O
mutations NNS O
in IN O
human JJ O
cancer NN O
occur VBP O
elsewhere RB O
in IN O
the DT O
DBD NNP O
and CC O
at IN O
a DT O
much RB O
lower JJR O
frequency NN O
. . O

We PRP O
report VBP O
here RB O
that IN O
mutations NNS B-Var
at IN I-Var
K120 NNP I-Var
, , O
a DT O
non-hotspot AFX O
DNA NN O
contact NN O
residue NN O
, , O
confer VB B-PosReg
p53 NN B-Gene
with IN O
the DT O
previously RB O
unrecognized JJ O
ability NN B-MPA
to TO O
bind VB B-Interaction
and CC O
activate VBP B-PosReg
the DT O
transcription NN B-MPA
of IN O
the DT O
pro-survival JJ O
TNFAIP8 NN B-Gene
gene NN O
. . O

Mutant NNP O
K120 NNP O
p53 NN O
binds NNS O
the DT O
TNFAIP8 NNP O
locus NN O
at IN O
a DT O
cryptic JJ O
p53 NN O
response NN O
element NN O
that WDT O
is VBZ O
not RB O
occupied VBN O
by IN O
wild-type JJ O
p53 NN O
. . O

Furthermore RB O
, , O
induction NN O
of IN O
TNFAIP8 NNP O
is VBZ O
critical JJ O
for IN O
the DT O
evasion NN O
of IN O
apoptosis NN O
by IN O
tumor NN O
cells NNS O
expressing VBG O
the DT O
K120R JJ O
variant NN O
of IN O
p53 NN O
. . O

These DT O
findings NNS O
identify VBP O
induction NN O
of IN O
pro-survival JJ O
targets NNS O
as IN O
a DT O
mechanism NN O
of IN O
gain-of-function NN B-PosReg
activity NN B-MPA
for IN O
mutant JJ B-Var
p53 NN B-Gene
De NNP O
Novo NNP O
Mutations NNPS B-Var
in IN O
SON NNP B-Gene
Disrupt NNP O
RNA NNP O
Splicing NN O
of IN O
Genes NNPS O
Essential NNP O
for IN O
Brain NNP O
Development NNP O
and CC O
Metabolism NNP O
, , O
Causing VBG B-Reg
an DT O
Intellectual-Disability NNP B-Disease
Syndrome NNP I-Disease
. . O

The DT O
overall JJ O
understanding NN O
of IN O
the DT O
molecular JJ O
etiologies NNS O
of IN O
intellectual JJ O
disability NN O
( -LRB- O
ID NNP O
) -RRB- O
and CC O
developmental JJ O
delay NN O
( -LRB- O
DD NNP O
) -RRB- O
is VBZ O
increasing VBG O
as IN O
next-generation JJ O
sequencing NN O
technologies NNS O
identify VBP O
genetic JJ O
variants NNS O
in IN O
individuals NNS O
with IN O
such JJ O
disorders NNS O
. . O

However RB O
, , O
detailed JJ O
analyses NNS O
conclusively RB O
confirming VBG O
these DT O
variants NNS O
, , O
as RB O
well RB O
as IN O
the DT O
underlying VBG O
molecular JJ O
mechanisms NNS O
explaining VBG O
the DT O
diseases NNS O
, , O
are VBP O
often RB O
lacking JJ O
. . O

Here RB O
, , O
we PRP O
report VBP O
on IN O
an DT O
ID NNP B-Disease
syndrome NN I-Disease
caused VBN O
by IN O
de FW O
novo NN O
heterozygous JJ O
loss-of-function NN B-NegReg
( -LRB- O
LoF NN O
) -RRB- O
mutations NNS B-Var
in IN O
SON NNP B-Gene
. . O

The DT O
syndrome NN O
is VBZ O
characterized VBN O
by IN O
ID NNP O
and/or CC O
DD NNP O
, , O
malformations NNS O
of IN O
the DT O
cerebral JJ O
cortex NN O
, , O
epilepsy NN O
, , O
vision NN O
problems NNS O
, , O
musculoskeletal JJ O
abnormalities NNS O
, , O
and CC O
congenital JJ O
malformations NNS O
. . O

Knockdown NNP O
of IN O
son NN O
in IN O
zebrafish NN O
resulted VBD O
in IN O
severe JJ O
malformation NN O
of IN O
the DT O
spine NN O
, , O
brain NN O
, , O
and CC O
eyes NNS O
. . O

Importantly RB O
, , O
analyses NNS O
of IN O
RNA NNP O
from IN O
affected VBN O
individuals NNS O
revealed VBN O
that IN O
genes NNS O
critical JJ O
for IN O
neuronal JJ B-CPA
migration NN I-CPA
and CC O
cortex NN B-CPA
organization NN I-CPA
( -LRB- O
TUBG1 NNP O
, , O
FLNA NNP O
, , O
PNKP NNP O
, , O
WDR62 NNP O
, , O
PSMD3 NNP O
, , O
and CC O
HDAC6 NNP O
) -RRB- O
and CC O
metabolism NN B-CPA
( -LRB- O
PCK2 NNP O
, , O
PFKL NNP O
, , O
IDH2 NNP O
, , O
ACY1 NNP O
, , O
and CC O
ADA NNP O
) -RRB- O
are VBP O
significantly RB O
downregulated VBN B-NegReg
because IN O
of IN O
the DT O
accumulation NN B-PosReg
of IN O
mis-spliced NN O
transcripts NNS O
resulting VBG O
from IN O
erroneous JJ B-Var
SON-mediated NN I-Var
RNA NNP I-Var
splicing NN I-Var
The DT O
anti-adipogenic RB B-MPA
effect NN I-MPA
of IN O
peripheral JJ O
blood NN O
mononuclear NN O
cells NNS O
is VBZ O
absent JJ B-NegReg
with IN O
PCSK9 NNS B-Gene
loss-of-function NN B-NegReg
variants NNS B-Var
. . O

OBJECTIVE NN O
: : O
To TO O
determine VB O
the DT O
effect NN O
of IN O
( -LRB- O
1 LS O
) -RRB- O
an DT O
oral JJ O
fat JJ O
load NN O
and CC O
( -LRB- O
2 LS O
) -RRB- O
pro-protein JJ O
convertase NN O
subtilisin NN O
/ SYM O
kexin NN O
type NN O
( -LRB- O
PCSK NNP O
) -RRB- O
9 CD O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
variant NN B-Var
status NN O
on IN O
the DT O
ability NN O
of IN O
peripheral JJ O
blood NN O
mononuclear NN O
cells NNS O
( -LRB- O
PBMC NNP O
) -RRB- O
to TO O
inhibit VB B-NegReg
human JJ B-MPA
adipogenesis NN I-MPA
. . O

METHODS NNS O
: : O
PBMC JJ O
from IN O
subjects NNS O
with IN O
one CD O
or CC O
more JJR O
PCSK9 NNS O
LOF NNP O
variants NNS O
versus IN O
non-variant AFX O
controls NNS O
were VBD O
compared VBN O
in IN O
the DT O
fasting VBG O
state NN O
and CC O
after IN O
an DT O
oral JJ O
fat JJ O
load NN O
. . O

RESULTS NNS O
: : O
Fasting VBG O
triglyceride NN O
( -LRB- O
TG NNP O
) -RRB- O
levels NNS O
were VBD O
lower JJR O
in IN O
the DT O
LOF NNP O
variant NN O
versus IN O
non-variant AFX O
group NN O
but CC O
rose VBD O
to IN O
the DT O
same JJ O
level NN O
after IN O
the DT O
oral JJ O
fat JJ O
load NN O
. . O

Conditioned VBN O
medium NN O
from IN O
PBMC NNP O
was VBD O
obtained VBN O
in IN O
fasting VBG O
( -LRB- O
PBMC-CM-F JJ O
) -RRB- O
and CC O
4-h CD O
postprandial JJ O
( -LRB- O
PBMC-CM-PP JJ O
) -RRB- O
states NNS O
. . O

PBMC-CM-PP JJ O
from IN O
non-variant AFX O
controls NNS O
inhibited VBD O
adipogenesis NN O
of IN O
human JJ O
preadipocytes VBZ O
more RBR O
than IN O
did VBD O
PBMC-CM-F. JJ O
In IN O
contrast NN O
, , O
PBMC-CM-F JJ O
or CC O
-PP HYPH O
from IN O
PCSK9 NNS B-Gene
LOF NNP B-NegReg
variant JJ B-Var
subjects NNS O
had VBD O
no DT O
effect NN O
on IN O
adipogenesis NN B-MPA
. . O

After IN O
the DT O
oral JJ O
fat JJ O
load NN O
, , O
PBMC VBN O
from IN O
PCSK9 NNS B-Gene
LOF NNP B-NegReg
variant JJ B-Var
subjects NNS O
showed VBD O
significant JJ O
increases NNS B-PosReg
in IN O
mRNA NNS B-MPA
levels NNS I-MPA
of IN I-MPA
, , O
tumor NN B-MPA
necrosis NN I-MPA
, , O
sterol VBP B-MPA
regulatory JJ I-MPA
element NN I-MPA
binding VBG I-MPA
protein-1c NNP I-MPA
, , O
CD36 NNP B-MPA
, , O
and CC O
monocyte JJ O
chemoattractant JJ O
protein-1 NN O
( -LRB- O
MCP-1 NNP O
) -RRB- O
, , O
only RB O
MCP-1 NNP O
mRNA NNS O
levels NNS O
increased VBD O
in IN O
PBMC NNP O
from IN O
non-variant AFX O
controls NNS O
. . O

CONCLUSIONS NNS O
: : O
The DT O
absence NN B-NegReg
of IN O
anti-adipogenic RB B-MPA
action NN I-MPA
of IN O
PBMC NNP O
from IN O
PCSK9 NNS B-Gene
LOF NNP O
variant JJ B-Var
subjects NNS O
points VBZ O
to IN O
a DT O
novel JJ B-PosReg
role NN I-PosReg
for IN O
PCSK9 NNS O
in IN O
PBMC-adipose NNP O
cell NN O
interactions NNS B-Interaction
Atopic NNP O
Dermatitis NNP O
Susceptibility NNP O
Variants NNPS O
in IN O
Filaggrin NNP O
Hitchhike NNP O
Hornerin NNP O
Selective NNP O
Sweep NNP O
. . O

Human NNP O
skin NN O
has VBZ O
evolved VBN O
rapidly RB O
, , O
leaving VBG O
evolutionary JJ O
signatures NNS O
in IN O
the DT O
genome NN O
. . O

The DT O
filaggrin NN O
( -LRB- O
FLG NNP B-Gene
) -RRB- O
gene NN O
is VBZ O
widely RB O
studied VBN O
for IN O
its PRP$ O
skin-barrier NN O
function NN O
in IN O
humans NNS O
. . O

The DT O
extensive JJ B-Var
genetic JJ I-Var
variation NN I-Var
in IN O
this DT O
gene NN O
, , O
especially RB O
common JJ O
loss-of-function NN B-NegReg
( -LRB- O
LoF NN O
) -RRB- O
mutations NNS B-Var
, , O
has VBZ O
been VBN O
established VBN O
as IN O
primary JJ O
risk NN O
factors NNS O
for IN O
atopic JJ B-Disease
dermatitis NN I-Disease
Variants NNS O
of IN O
genes NNS O
encoding VBG O
collagens NNS O
and CC O
matrix NN O
metalloproteinase NN O
system NN O
increased VBD O
the DT O
risk NN O
of IN O
aortic JJ O
dissection NN O
. . O

Aortic JJ O
dissection NN O
( -LRB- O
AD NN O
) -RRB- O
is VBZ O
a DT O
devastating JJ O
, , O
heterogeneous JJ O
condition NN O
of IN O
aorta NNS O
. . O

The DT O
homeostasis NN O
between IN O
collagens NNS O
and CC O
matrix NN O
metalloproteases NNS O
( -LRB- O
MMPs)/tissue NN O
inhibitors NNS O
of IN O
MMPs NNS O
( -LRB- O
TIMPs NNP O
) -RRB- O
system NN O
in IN O
the DT O
extracellular JJ O
matrix NN O
plays VBZ O
an DT O
important JJ O
role NN O
for IN O
structure NN O
and CC O
functions NNS O
of IN O
aorta NNS O
. . O

However RB O
, , O
our PRP$ O
knowledge NN O
on IN O
association NN O
between IN O
variants NNS O
of IN O
genes NNS O
in IN O
this DT O
system NN O
and CC O
pathogenesis NN O
of IN O
AD NN O
is VBZ O
very RB O
limited JJ O
. . O

We PRP O
analyzed VBD O
all DT O
yet RB O
known VBN O
coding VBG O
human JJ O
genes NNS O
of IN O
collagens NNS O
( -LRB- O
45 CD O
genes NNS O
) -RRB- O
, , O
MMPs NNP O
/ SYM O
TIMPs NNP O
( -LRB- O
27 CD O
genes NNS O
) -RRB- O
in IN O
702 CD O
sporadic JJ O
AD NN O
patients NNS O
and CC O
in IN O
163 CD O
matched VBN O
healthy JJ O
controls NNS O
, , O
by IN O
using VBG O
massively RB O
targeted VBN O
next-generation JJ O
and CC O
Sanger NNP O
sequencing NN O
. . O

To TO O
define VB O
the DT O
pathogenesis NN O
of IN O
potential JJ O
disease-causing NN O
candidate NN O
genes NNS O
, , O
we PRP O
performed VBD O
transcriptome VBP O
sequencing NN O
and CC O
pedigree JJ O
co-segregation NN O
analysis NN O
in IN O
some DT O
genes NNS O
and CC O
generated VBD O
Col5a2 NNP O
knockout NN O
rats NNS O
. . O

We PRP O
identified VBD O
257 CD O
pathogenic JJ O
or CC O
likely JJ O
pathogenic JJ O
variants NNS O
which WDT O
involved VBD O
88.89 CD O
% NN O
( -LRB- O
64/72 CD O
) -RRB- O
genes NNS O
in IN O
collagens-MMPs NNS O
/ SYM O
TIMPs NNP O
system NN O
and CC O
accounted VBD O
for IN O
31.05 CD O
% NN O
( -LRB- O
218/702 CD O
) -RRB- O
sporadic JJ O
AD NN O
patients NNS O
. . O

In IN O
them PRP O
, , O
84.86 CD O
% NN O
patients NNS O
( -LRB- O
185/218 CD O
) -RRB- O
carried VBD O
one CD O
variant NN O
, , O
12.84 CD O
% NN O
two CD O
variants NNS O
and CC O
2.30 CD O
% NN O
more JJR O
than IN O
two CD O
variants NNS O
. . O

Importantly RB O
, , O
we PRP O
identified VBD O
52 CD O
novel NN O
probably RB O
pathogenic JJ O
loss-of-function NN O
( -LRB- O
LOF NNP O
) -RRB- O
variants NNS O
( -LRB- O
20 CD O
nonsense NN O
, , O
16 CD O
frameshift NN O
, , O
14 CD O
splice NN O
sites NNS O
, , O
one CD O
stop-loss VB O
, , O
one CD O
initiation NN O
codon NN O
) -RRB- O
in IN O
11.06 CD O
% NN O
( -LRB- O
50/452 CD O
) -RRB- O
AD NN O
patients NNS O
, , O
which WDT O
were VBD O
absent JJ O
in IN O
163 CD O
controls NNS O
( -LRB- O
) -RRB- O
) -RRB- O
. . O

Transcriptome VB O
sequencing NN O
revealed VBD O
that IN O
identified VBN O
variants NNS B-Var
induced VBD O
dyshomeostasis NN B-Reg
in IN O
expression NN B-CPA
of IN I-CPA
collagens-TIMPs NNP I-CPA
/ SYM I-CPA
MMPs NNP O
systems NNS O
. . O

The DT O
Col5a2 NNP B-Gene
( -LRB- O
-/- SYM O
) -RRB- O
rats NNS O
manifested VBD O
growth NN B-CPA
retardation NN I-CPA
and CC O
aortic JJ B-CPA
dysplasia NN I-CPA
Alanine-scanning NN O
mutagenesis NN O
of IN O
human JJ O
signal NN O
transducer NN O
and CC O
activator NN O
of IN O
transcription NN O
1 CD O
to TO O
estimate VB O
loss- VBD O
or CC O
gain-of-function VB O
variants NNS O
. . O

BACKGROUND NNP O
: : O
Germline JJ B-Var
heterozygous JJ I-Var
mutations NNS I-Var
in IN O
human JJ O
signal NN B-Gene
transducer NN I-Gene
and CC O
activator NN B-Gene
of IN I-Gene
transcription NN I-Gene
1 CD I-Gene
( -LRB- O
STAT1 NNP O
) -RRB- O
can MD O
cause VB O
loss NN B-NegReg
of IN I-NegReg
function NN I-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
, , O
as IN O
in IN O
patients NNS O
with IN O
Mendelian JJ O
susceptibility NN O
to IN O
mycobacterial JJ B-Disease
diseases NNS I-Disease
, , O
or CC O
gain NN B-PosReg
of IN I-PosReg
function NN I-PosReg
( -LRB- O
GOF NN O
) -RRB- O
, , O
as IN O
in IN O
patients NNS O
with IN O
chronic JJ B-Disease
mucocutaneous JJ I-Disease
candidiasis NN I-Disease
. . O

LOF NNP O
and CC O
GOF NN O
mutations NNS B-Var
are VBP O
equally RB O
rare JJ O
and CC O
can MD O
affect VB B-Reg
the DT O
same JJ O
domains NNS B-MPA
of IN O
STAT1 NNP B-Gene
, , O
especially RB O
the DT O
coiled-coil VBN B-MPA
domain NN I-MPA
( -LRB- O
CCD NNP O
) -RRB- O
and CC O
DNA-binding NN B-MPA
domain NN I-MPA
Ruxolitinib NNP O
reverses NNS O
dysregulated VBD O
T NNP O
helper NN O
cell NN O
responses NNS O
and CC O
controls NNS O
autoimmunity NN O
caused VBN O
by IN O
a DT O
novel JJ O
signal NN O
transducer NN O
and CC O
activator NN O
of IN O
transcription NN O
1 CD O
( -LRB- O
STAT1 NNP O
) -RRB- O
gain-of-function NN O
mutation NN O
. . O

BACKGROUND NNP O
: : O
Gain-of-function NNP B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
mutations NNS B-Var
in IN O
the DT O
human JJ B-Gene
signal NN I-Gene
transducer NN I-Gene
and CC I-Gene
activator NN I-Gene
of IN I-Gene
transcription NN I-Gene
1 CD I-Gene
( -LRB- O
STAT1 NNP O
) -RRB- O
manifest VBP O
in IN O
immunodeficiency NN O
and CC O
autoimmunity NN O
with IN O
impaired VBN B-NegReg
TH17 NNP B-CPA
cell NN O
differentiation NN O
and CC O
exaggerated JJ B-PosReg
responsiveness NN B-Interaction
to TO I-Interaction
type VB I-Interaction
I PRP I-Interaction
and CC I-Interaction
II NNP I-Interaction
interferons NNS I-Interaction
. . O

Allogeneic JJ O
bone NN O
marrow NN O
transplantation NN O
has VBZ O
been VBN O
attempted VBN O
in IN O
severely RB O
affected VBN O
patients NNS O
, , O
but CC O
outcomes NNS O
have VBP O
been VBN O
poor JJ O
. . O

OBJECTIVE NN O
: : O
We PRP O
sought VBD O
to TO O
define VB O
the DT O
effect NN O
of IN O
increased VBN O
STAT1 NNP O
activity NN O
on IN O
T NNP O
helper NN O
cell NN O
polarization NN O
and CC O
to TO O
investigate VB O
the DT O
therapeutic JJ O
potential NN O
of IN O
ruxolitinib NN O
in IN O
treating VBG O
autoimmunity NN O
secondary JJ O
to IN O
STAT1 NNP O
GOF NN O
mutations NNS O
. . O

METHODS NNS O
: : O
We PRP O
used VBD O
in IN O
vitro FW O
polarization NN O
assays NNS O
, , O
as RB O
well RB O
as IN O
phenotypic NN O
and CC O
functional JJ O
analysis NN O
of IN O
STAT1-mutated VBN O
patient NN O
cells NNS O
. . O

RESULTS NNS O
: : O
We PRP O
report VBP O
a DT O
child NN O
with IN O
a DT O
novel JJ O
mutation NN B-Var
in IN I-Var
the DT I-Var
linker NN I-Var
domain NN I-Var
of IN O
STAT1 NNP B-Gene
who WP O
had VBD O
life-threatening NN O
autoimmune JJ O
cytopenias NNS O
and CC O
chronic JJ O
mucocutaneous JJ O
candidiasis NN O
. . O

Naive JJ O
lymphocytes NNS O
from IN O
the DT O
affected JJ O
patient NN O
displayed VBN O
increased VBN B-PosReg
TH1 NNP B-CPA
and CC I-CPA
follicular JJ I-CPA
T NNP I-CPA
helper NN I-CPA
cell NN I-CPA
and CC O
suppressed VBD B-NegReg
TH17 NNP B-CPA
cell NN O
responses NNS O
. . O

The DT O
mutation NN B-Var
augmented VBD B-PosReg
cytokine-induced NN B-MPA
STAT1 NNP I-MPA
phosphorylation NN I-MPA
without IN O
affecting VBG O
dephosphorylation NN O
kinetics NNS O
. . O

Treatment NN O
with IN O
the DT O
Janus NNP O
kinase NN O
1/2 CD O
inhibitor NN O
ruxolitinib NN O
reduced VBN O
hyperresponsiveness NN O
to TO O
type VB O
I PRP O
and CC O
II NNP O
interferons NNS O
, , O
normalized VBD O
TH1 NNP O
and CC O
follicular JJ O
T NNP O
helper NN O
cell NN O
responses NNS O
, , O
improved VBD O
TH17 NNP O
differentiation NN O
, , O
cured VBN O
mucocutaneous JJ O
candidiasis NN O
, , O
and CC O
maintained VBN O
remission NN O
of IN O
immune-mediated NN O
cytopenias NNS O
. . O

CONCLUSIONS NNS O
: : O
Autoimmunity NN O
and CC O
infection NN O
caused VBN O
by IN O
STAT1 NNP B-Gene
GOF NN B-PosReg
mutations NNS B-Var
are VBP O
the DT O
result NN O
of IN O
dysregulated JJ O
T NNP B-CPA
helper NN I-CPA
cell NN I-CPA
responses NNS I-CPA
Complexity NN O
of IN O
mechanisms NNS O
among IN O
human JJ O
proprotein NN O
convertase NN O
subtilisin-kexin NN O
type NN O
9 CD O
variants NNS O
. . O

PURPOSE NN O
OF IN O
REVIEW NNS O
: : O
There EX O
are VBP O
many JJ O
reports NNS O
of IN O
human JJ O
variants NNS B-Var
in IN O
proprotein NN O
convertase NN O
subtilisin-kexin NN O
type NN O
9 CD O
( -LRB- O
PCSK9 NNS B-Gene
) -RRB- O
that WDT O
are VBP O
either CC O
gain-of-function JJ B-PosReg
( -LRB- O
GOF NN O
) -RRB- O
or CC O
loss-of-function NN B-NegReg
( -LRB- O
LOF NNP O
) -RRB- O
, , O
with IN O
downstream JJ O
effects NNS B-Reg
on IN O
LDL NNP B-Disease
cholesterol NN I-Disease
and CC O
cardiovascular JJ B-Disease
disease NN I-Disease
( -LRB- O
CVD NN O
) -RRB- O
risk NN O
. . O

However RB O
, , O
data NNS O
on IN O
particular JJ O
mechanisms NNS O
have VBP O
only RB O
been VBN O
minimally RB O
curated VBN O
. . O

RECENT JJ O
FINDINGS NNS O
: : O
GOF NN B-PosReg
variants NNS B-Var
are VBP O
individually RB O
ultrarare JJ O
, , O
affect VB B-Reg
all DT O
domains NNS B-Protein
of IN I-Protein
the DT I-Protein
protein NN I-Protein
, , O
act VBP O
to TO O
reduce VB B-NegReg
LDL NNP B-Protein
receptor NN I-Protein
expression NN B-MPA
through IN O
several JJ O
mechanisms NNS O
, , O
are VBP O
a DT O
minor JJ O
cause NN B-Reg
of IN O
familial JJ B-Disease
hypercholesterolemia NN I-Disease
, , O
have VBP O
been VBN O
reported VBN O
mainly RB O
within IN O
families NNS O
, , O
have VBP O
variable JJ O
LDL NNP O
cholesterol-raising NN O
effects NNS O
, , O
and CC O
are VBP O
associated VBN O
with IN O
increased VBN O
CVD NN O
risk NN O
mainly RB O
through IN O
observational JJ O
studies NNS O
in IN O
families NNS O
and CC O
small JJ O
cohorts NNS O
. . O

In IN O
contrast NN O
, , O
LOF NNP B-NegReg
variants NNS B-Var
can MD O
be VB O
either CC O
ultrarare JJ O
mutations NNS O
or CC O
relatively RB O
more RBR O
common JJ O
polymorphisms NNS O
seen VBN O
in IN O
populations NNS O
, , O
affect VB B-Reg
all DT O
domains NNS B-Protein
of IN I-Protein
the DT I-Protein
protein NN I-Protein
, , O
act VBP O
to TO O
increase VB B-PosReg
LDL NNP B-Protein
receptor NN I-Protein
expression NN B-MPA
through IN O
several JJ O
mechanisms NNS O
, , O
have VBP O
variable JJ O
LDL NNP B-MPA
cholesterol-lowering NN I-MPA
effects NNS O
, , O
and CC O
have VBP O
been VBN O
associated VBN O
with IN O
decreased VBN O
CVD NN O
risk NN O
mainly RB O
through IN O
Mendelian JJ O
randomization NN O
studies NNS O
in IN O
epidemiologic JJ O
populations NNS O
. . O

SUMMARY NNP O
: : O
There EX O
is VBZ O
considerable JJ O
complexity NN O
underlying VBG O
the DT O
clinical JJ O
concept NN O
of IN O
both CC O
LOF NNP O
and CC O
GOF NN O
variants NNS O
of IN O
PCSK9 NNS O
. . O

But CC O
despite IN O
the DT O
underlying JJ O
mechanistic JJ O
heterogeneity NN O
, , O
altered VBN O
PCSK9 NNS O
secretion NN O
or CC O
function NN O
is VBZ O
ultimately RB O
correlated VBN O
with IN O
plasma NN O
LDL NNP O
cholesterol NN O
level NN O
, , O
which WDT O
is VBZ O
also RB O
the DT O
driver NN O
of IN O
CVD NNP O
outcomes NNS O
. . O

Towards IN O
trans-diagnostic NNS O
mechanisms NNS O
in IN O
psychiatry NN O
: : O
neurobehavioral JJ O
profile NN O
of IN O
rats NNS O
with IN O
a DT O
loss-of-function NN O
point NN O
mutation NN O
in IN O
the DT O
dopamine NN O
transporter NN O
gene NN O
. . O

The DT O
research NN O
domain NN O
criteria NNS O
( -LRB- O
RDoC NN O
) -RRB- O
matrix NN O
has VBZ O
been VBN O
developed VBN O
to TO O
reorient VB O
psychiatric JJ O
research NN O
towards IN O
measurable JJ O
behavioral JJ O
dimensions NNS O
and CC O
underlying JJ O
mechanisms NNS O
. . O

Here RB O
, , O
we PRP O
used VBD O
a DT O
new JJ O
genetic JJ O
rat NN O
model NN O
with IN O
a DT O
loss-of-function NN O
point NN O
mutation NN O
in IN O
the DT O
dopamine NN O
transporter NN O
( -LRB- O
DAT NNP O
) -RRB- O
gene NN O
( -LRB- O
Slc6a3_N157 NN O
K NNP O
) -RRB- O
to TO O
systematically RB O
study VB O
the DT O
RDoC NN O
matrix NN O
. . O

First RB O
, , O
we PRP O
examined VBD O
the DT O
impact NN O
of IN O
the DT O
Slc6a3_N157 NN O
K NNP O
mutation NN O
on IN O
monoaminergic NN O
signaling NN O
. . O

We PRP O
then RB O
performed VBD O
behavioral JJ O
tests NNS O
representing VBG O
each DT O
of IN O
the DT O
five CD O
RDoC NN O
domains NNS O
: : O
negative JJ O
and CC O
positive JJ O
valence NN O
systems NNS O
, , O
cognitive JJ O
, , O
social JJ O
and CC O
arousal NN O
/ SYM O
regulatory JJ O
systems NNS O
. . O

The DT O
use NN O
of IN O
RDoC NN O
may MD O
be VB O
particularly RB O
helpful JJ O
for IN O
drug NN O
development NN O
. . O

We PRP O
studied VBD O
the DT O
effects NNS O
of IN O
a DT O
novel JJ O
pharmacological JJ O
approach NN O
metabotropic JJ O
glutamate JJ O
receptor NN O
mGluR2/3 VBD O
antagonism NN O
, , O
in IN O
DAT NNP O
mutants NNS O
in IN O
a DT O
comparative JJ O
way NN O
with IN O
standard JJ O
medications NNS O
. . O

Loss NN B-NegReg
of IN O
DAT NNP B-Gene
functionality NN O
in IN O
mutant JJ B-Var
rats NNS O
not RB O
only RB O
elevated JJ B-PosReg
subcortical JJ B-MPA
extracellular JJ I-MPA
dopamine NN I-MPA
concentration NN I-MPA
but CC O
also RB O
altered VBD B-Reg
the DT O
balance NN B-MPA
of IN I-MPA
monoaminergic JJ I-MPA
transmission NN I-MPA
Conformational JJ O
disruption NN O
of IN O
regulation NN O
by IN O
immunodeficiency NN O
mutations NNS O
in IN O
PIK3CD NNP O
and CC O
PIK3R1 NNP O
. . O

Activated VBN B-Disease
PI3 NNP I-Disease
K NNP I-Disease
Delta NNP I-Disease
Syndrome NNP O
( -LRB- O
APDS NNP O
) -RRB- O
is VBZ O
a DT O
primary JJ O
immunodeficiency NN O
disease NN O
caused VBN B-Reg
by IN O
activating VBG O
mutations NNS B-Var
in IN O
either CC O
the DT O
leukocyte-restricted NN O
catalytic NN O
( -LRB- O
PIK3CD NNP B-Gene
) -RRB- O
subunit NN O
or CC O
the DT O
ubiquitously RB O
expressed VBN O
regulatory JJ O
( -LRB- O
PIK3R1 NN O
) -RRB- O
subunit NN O
of IN O
class NN O
IA NNP O
phosphoinositide NN O
3-kinases NNS O
( -LRB- O
PI3Ks NNP O
) -RRB- O
. . O

There EX O
are VBP O
two CD O
classes NNS O
of IN O
APDS NNPS O
: : O
APDS1 NNS O
that WDT O
arises VBZ O
from IN O
mutations NNS O
that WDT O
are VBP O
analogous JJ O
to IN O
oncogenic JJ O
mutations NNS O
found VBN O
in IN O
the DT O
broadly RB O
expressed VBN O
subunit NN O
and CC O
APDS2 VBD O
that DT O
occurs VBZ O
from IN O
a DT O
splice NN O
mutation NN O
resulting VBG O
in IN O
with IN O
a DT O
central JJ O
deletion NN O
( -LRB- O
) -RRB- O
. . O

As IN O
p85 NN O
regulatory JJ O
subunits NNS O
associate NN O
with IN O
and CC O
inhibit VB O
all DT O
class NN O
IA NN O
catalytic JJ O
subunits NNS O
, , O
APDS2 JJ O
mutations NNS O
are VBP O
expected VBN O
to TO O
similarly RB O
activate VB O
, , O
, , O
and CC O
, , O
yet CC O
APDS2 VBN O
largely RB O
phenocopies NNS O
APDS1 NNS O
without IN O
dramatic JJ O
effects NNS O
outside IN O
the DT O
immune JJ O
system NN O
. . O

We PRP O
have VBP O
examined VBN O
the DT O
molecular JJ O
mechanism NN O
of IN O
activation NN O
of IN O
both DT O
classes NNS O
of IN O
APDS NNP O
mutations NNS O
using VBG O
a DT O
combination NN O
of IN O
biochemical JJ O
assays NNS O
and CC O
hydrogen-deuterium NN O
exchange NN O
mass NN O
spectrometry NN O
. . O

Intriguingly RB O
, , O
we PRP O
find VBP O
that IN O
an DT O
APDS2 JJ B-Gene
mutation NN B-Var
in IN O
leads NNS O
to IN O
substantial JJ O
basal NN O
activation NN B-PosReg
of IN O
( -LRB- I-MPA
> XX O
300-fold CD O
) -RRB- O
and CC O
disrupts VBZ B-NegReg
inhibitory JJ B-MPA
interactions NNS I-MPA
N-cadherin NNP O
Regulation NNP O
of IN O
Bone NNP O
Growth NNP O
and CC O
Homeostasis NNP O
Is VBZ O
Osteolineage NNP O
Stage-Specific NNP O
. . O

N-cadherin NNP O
inhibits VBZ O
osteogenic JJ O
cell NN O
differentiation NN O
and CC O
canonical JJ O
signaling NN O
in IN O
vitro FW O
. . O

However RB O
, , O
in IN O
vivo NN O
both CC O
conditional JJ O
Cdh2 NN O
ablation NN O
and CC O
overexpression NN O
in IN O
osteoblasts NNS O
lead VBP O
to IN O
low JJ O
bone NN O
mass NN O
. . O

We PRP O
tested VBD O
the DT O
hypothesis NN O
that WDT O
N-cadherin NNP O
has VBZ O
different JJ O
effects NNS O
on IN O
osteolineage NN O
cells NNS O
depending VBG O
upon IN O
their PRP$ O
differentiation NN O
stage NN O
. . O

Embryonic JJ O
conditional JJ O
osteolineage NN O
Cdh2 NN B-Gene
deletion NN B-Var
in IN O
mice NN O
results NNS O
in IN O
defective JJ B-NegReg
growth NN B-MPA
, , O
low JJ B-NegReg
bone NN B-MPA
mass NN I-MPA
, , O
and CC O
reduced VBN B-NegReg
osteoprogenitor NN B-MPA
number NN I-MPA
MAX NNP O
inactivation NN O
is VBZ O
an DT O
early JJ O
event NN O
in IN O
GIST NNP O
development NN O
that WDT O
regulates VBZ O
p16 NN O
and CC O
cell NN O
proliferation NN O
. . O

KIT NNP B-Gene
, , O
PDGFRA NNP B-Gene
, , O
NF1 NNP B-Gene
and CC O
SDH NNP B-Gene
mutations NNS B-Var
are VBP O
alternate JJ O
initiating VBG O
events NNS O
, , O
fostering VBG B-Reg
hyperplasia NN O
in IN O
gastrointestinal JJ B-MPA
stromal JJ I-MPA
tumours NNS I-MPA
ATR NNP B-Gene
Mutations NNPS B-Var
Promote NNP B-PosReg
the DT O
Growth NNP B-MPA
of IN O
Melanoma NNP B-Disease
Tumors NNS I-Disease
by IN O
Modulating VBG O
the DT O
Immune NNP O
Microenvironment NNP O
. . O

Melanomas NNP O
accumulate VBP O
a DT O
high JJ O
burden NN O
of IN O
mutations NNS B-Var
that WDT O
could MD O
potentially RB O
generate VB B-Reg
neoantigens NNS B-MPA
, , O
yet CC O
somehow RB O
suppress VBP B-NegReg
the DT O
immune JJ B-MPA
response NN I-MPA
to TO I-MPA
facilitate VB I-MPA
continued JJ I-MPA
growth NN I-MPA
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
identify VBP O
a DT O
subset NN O
of IN O
human JJ O
melanomas NNS O
that WDT O
have VBP O
loss-of-function NN O
mutations NNS O
in IN O
ATR NNP O
, , O
a DT O
kinase NN O
that WDT O
recognizes VBZ O
and CC O
repairs NNS O
UV-induced NN O
DNA NN O
damage NN O
and CC O
is VBZ O
required VBN O
for IN O
cellular JJ O
proliferation NN O
. . O

ATR NN B-Gene
mutant JJ B-Var
tumors NNS O
exhibit VBP O
both CC O
the DT O
accumulation NN O
of IN O
multiple JJ O
mutations NNS O
and CC O
the DT O
altered JJ O
expression NN O
of IN O
inflammatory JJ O
genes NNS O
, , O
resulting VBG O
in IN O
decreased JJ B-NegReg
T NNP B-MPA
cell NN O
recruitment NN O
and CC O
increased VBD B-PosReg
recruitment NN B-MPA
of IN I-MPA
macrophages NNS I-MPA
Regulation NN O
of IN O
endometrial JJ O
cell NN O
proliferation NN O
by IN O
estrogen-induced NN O
BDNF NNP O
signaling NN O
pathway NN O
. . O

Brain-derived NN O
neurotrophic JJ O
factor NN O
( -LRB- O
BDNF NNP O
) -RRB- O
is VBZ O
a DT O
member NN O
of IN O
the DT O
neurotrophin JJ O
growth NN O
factors NNS O
family NN O
. . O

Recent JJ O
studies NNS O
indicated VBD O
that IN O
the DT O
level NN O
of IN O
BDNF NNP O
in IN O
follicular JJ O
fluid NN O
is VBZ O
a DT O
marker NN O
for IN O
oocyte NN O
quality NN O
and CC O
infertility NN O
. . O

Here RB O
, , O
we PRP O
intend VBP O
to TO O
further RB O
investigate VB O
the DT O
function NN O
of IN O
BDNF NNP O
and CC O
its PRP$ O
signaling NN O
pathway NN O
in IN O
the DT O
regulation NN O
of IN O
endometrial JJ O
cells NNS O
proliferation NN O
. . O

We PRP O
found VBD O
that IN O
BDNF NNP O
is VBZ O
a DT O
critical JJ O
growth NN O
factor NN O
in IN O
endometrial JJ O
cells NNS O
. . O

Activation NN O
of IN O
signal NN O
transducer NN O
and CC O
activator NN O
of IN O
transcription NN O
3 CD O
signaling NN O
pathway NN O
is VBZ O
required VBN O
for IN O
BNDF-regulated NNS O
endometrial JJ O
cell NN O
proliferation NN O
. . O

Furthermore RB O
, , O
BDNF NNP O
is VBZ O
an DT O
effector NN O
of IN O
estrogen NN O
in IN O
endometrial JJ O
cells NNS O
. . O

Finally RB O
, , O
we PRP O
investigated VBD O
the DT O
different JJ O
role NN O
of IN O
Val66Met NNP O
, , O
a DT O
single-nucleotide JJ O
polymorphism NN O
of IN O
the DT O
BDNF NNP O
gene NN O
, , O
in IN O
regulating VBG O
endometrial NN O
cells NNS O
proliferation NN O
. . O

The DT O
results NNS O
showed VBD O
that IN O
BDNF(V66 `` B-Gene
M NNP O
) -RRB- O
polymorphism NN B-Var
is VBZ O
a DT O
loss-of-function NN B-NegReg
polymorphism NN B-Var
in IN O
the DT O
regulation NN B-MPA
of IN I-MPA
endometrial JJ I-MPA
cells NNS I-MPA
growth NN I-MPA
